Document:

Exhibit 10.60

 

 

 

License, SUPPLY

and Distribution
Agreement

 

Elite pharmaceuticals,
inc.,

 

elite laboratories,
inc.,

 

- and -

 

GLENMARK PHARMACEUTICALS
Inc., USA

 

Dated as of May 22, 2018

 

 

 

     

     

    

 

THIS LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT
is made as of May 22, 2018 (the “Effective Date”), by and between ELITE PHARMACEUTICALS, INC. and ELITE
LABORATORIES, INC., Nevada corporations located at 165 Ludlow Avenue, Northvale, New Jersey 07647 (collectively, “ELITE”),
and GLENMARK PHARMACEUTICALS INC., USA, a Delaware corporation located at 750 Corporate Drive, Mahwah, New Jersey 07430 (“GLENMARK”).

 

WHEREAS:

 

		A.	ELITE has ownership rights to products and/or ANDAs specified on Schedule A (the “Products”),
and GLENMARK wishes to license from ELITE the semi-exclusive and/or exclusive rights, as the case may be, to market and sell the
Products on the terms and conditions set forth in this Agreement.

 

		B.	ELITE has significant experience in developing, manufacturing and marketing finished dosage forms
of pharmaceutical products, including the Products;

 

		C.	GLENMARK has significant experience in marketing pharmaceutical products; and

 

		D.	Subject to the terms and conditions of this Agreement, GLENMARK desires to engage ELITE on an exclusive
basis to manufacture, supply, package and label the Products and ELITE agrees to grant GLENMARK the right under this Agreement
to commercialize the Products in the Territory on a semi-exclusive and/or exclusive basis.

 

NOW, THEREFORE in consideration of the
mutual covenants and obligations contained herein and other good and valuable consideration, the receipt and sufficiency of which
is hereby acknowledged, the Parties hereto agree as follows:

 

ARTICLE
1 - DEFINITIONS

 

		1.1	In addition to terms defined elsewhere in this Agreement, the terms set forth below shall be defined
in this Agreement (including the recitals) as follows:

 

		(a)	“Affiliate” with respect to either Party means any Person who directly or indirectly
through one or more intermediaries controls, is controlled by, or is under common control with such Party. The term “control”
means the beneficial (direct or indirect) ownership of more than fifty-percent (50%) of the voting or equity interests of such
Person or the power or right to direct the management and affairs of its business, whether through the ownership of voting securities,
by contract, or otherwise.

 

		(b)	“Agreement” means this License, Supply and Distribution Agreement, together
with all schedules hereto.

 

		(c)	“ANDA” means an Abbreviated New Drug Application pursuant to Section 505(j)
of the FDCA.

 

		(d)	“Bankruptcy Code” has the meaning given in Article 13.16.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	1

     

    

 

		(e)	“Business Day” in relation to each Party means any day other than a Saturday,
a Sunday, or any statutory or public holiday on which banks are generally closed for regular business in New York, New York.

 

		(f)	“Certificate of Analysis” means a certificate of analysis that certifies that
a given batch of Product meets the release Manufacturing Requirements.

 

		(g)	“Claim” means any claim, action, cause of action, or demand.

 

		(h)	“Commercially Reasonable Efforts” with respect to any activity means the efforts
and resources that would be used in the performance of the relevant activity in compliance with Law by a Person (engaged in the
manufacture and supply or distribution, sale and commercialization of pharmaceutical products, as applicable) of comparable size
and resources as the applicable Party with regard to a product at a similar stage in its product life taking into account the following
factors to the extent reasonable and relevant: issues of safety and efficacy, product profile, market potential, competitive market
conditions, duration of exclusivity or other proprietary position of the product and the potential profitability and economic return
of the product, all as measured by the facts and circumstances at the time such efforts are due.

 

		(i)	“Confidential Information” has the meaning given in Article 12.2.

 

		(j)	“DEA” shall mean the United States Drug Enforcement Administration or any successor
entity.

 

		(k)	“Debarred Entity” has the meaning given in Article 9.2(c).

 

		(l)	“Debarred Individual” has the meaning given in Article 9.2(c).

 

		(m)	“Distribution Fees” means {***} percent ({***}%) of Net Sales
for each Product that is DEA schedule II and {***}percent ({***}%) of Net Sales for all other Products.

 

		(n)	“Effective Date” has the meaning given in the preamble.

 

		(o)	“Facility” means the ELITE FDA-approved
manufacturing site located at Ludlow Avenue, Northvale, New Jersey 07647.

 

		(p)	“FDA” means the United States Food and Drug Administration or any successor
government agency.

 

		(q)	“FDCA” means the Federal Food, Drug, and Cosmetic Act.

 

		(r)	“Force Majeure Event” has the meaning given in Article 13.5.

 

		(s)	“ELITE” has the meaning given in the preamble.

 

		(t)	“GLENMARK” has the meaning given in the preamble.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	2

     

    

 

		(u)	“GMP” means current good manufacturing practices for the manufacture of finished
pharmaceutical products in effect within the Territory from time to time during the Term of this Agreement, which set
minimum standards to ensure that pharmaceutical products meet established requirements for identity, strength, quality and purity,
as established under the Laws of the Territory, including 21 C.F.R. Parts 210 and 211.

 

		(v)	“Gross Profit” means the Net Sales of a Product each calendar quarter less Transfer
Price of Product, Distribution Fees and shipping costs from the Facility.

 

		(w)	“Gross Sales” means the gross amount invoiced by GLENMARK or its Affiliates
or sublicensees for sales of the Product to Third Parties in the Territory.

 

		(x)	“Indemnitee” has the meaning given in Article 11.3.

 

		(y)	“Indemnitor” has the meaning given in Article 11.3.

 

		(z)	“Intellectual Property Rights” means any patent, trademark, copyright, trade
secret, right in unpatented know-how, right of confidence and any other intellectual or industrial property right of any nature
whatsoever in any part of the world, whether registered or unregistered.

 

		(aa)	“Law” means any federal, state, provincial and local laws, statutes, regulations,
rules, guidelines, orders, ordinances, and any other requirements of any government or Regulatory Authority applicable to the development,
registration, manufacturing, testing, packaging, storing, shipping, marketing, distribution and sale of pharmaceutical products
or as otherwise applicable to the Parties respective obligations under this Agreement, including the FDCA.

 

		(bb)	“Losses” means any damages, liabilities, obligations, costs, expenses or losses,
including reasonable legal fees and expenses, court costs, arbitration fees, penalties, fines, costs of investigation and amounts
paid in settlement of claims.

 

		(cc)	“Major Change” shall mean a change that has the potential to adversely impact
quality, identity, purity or stability of the Products or the compliance and validity of the Products Marketing Authorizations,
as these factors may relate the safety or efficacy of the Product. For example: lowering the purity requirement for a starting
material may adversely affect the quality of the Product and would be considered a Major Change. Tightening the purity requirement
of a starting material cannot negatively affect the quality of the Product and may be considered a minor change.

 

		(dd)	“Manufacturing Requirements” has the meaning given in Article 4.1(a).

 

		(ee)	“Marketing Authorization” means all approvals, licenses, registrations or authorizations
of any Regulatory Authority, necessary for the manufacturing, use, storage, import, transport, marketing, promotion and sale of
the Product in the Territory, together with pricing or reimbursement approval in countries where governmental approval is required
for pricing or for the Product to be reimbursed by national health insurance.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	3

     

    

 

		(ff)	“Net Sales” shall mean with respect to the Product, Gross Sales less the following
items (whether or not separately stated on such invoice but only to the extent included in Gross Sales):

 

		(i)	Any and all promotional allowances, rebates, charge backs, quantity and cash discounts, and other
usual and customary discounts to customers;

 

		(ii)	Amounts refunded, repaid or credited by reason of rejections, returns or recalls of goods;

 

		(iii)	Any sales, excise, turnover, inventory, value-added, and similar taxes and duties assessed on applicable
sales;

 

		(iv)	Failure to supply penalties (in the case if Article 4.4 (i) and (ii), Non-affiliate third party
administrative fees granted, Medicaid and state and/or governmental rebates, and shelf stock adjustments and retroactive price
reductions.

 

Components of Net
Sales shall be determined using the accrual method of accounting in accordance with US GAAP or an equivalent stipulated method
of accounting in the Territory.

 

		(gg)	“Non-Conforming Product” has the meaning given in Article 4.8(b).

 

		(hh)	“Original Agreement” has the meaning given in Recital A.

 

		(ii)	“Packaging” means all material used to prepare fully packaged Products, including
labelling, containers, cartons, shipping cases, and inserts, as applicable.

 

		(jj)	“Parties” means the parties to this Agreement referred to collectively, and
“Party” means either party to this Agreement referred to individually.

 

		(kk)	“Person” includes any individual, partnership, corporation, unincorporated organization
or association, joint venture, limited liability company, trust or any other form of entity.

 

		(ll)	“Pharmacovigilance Agreement” means the pharmacovigilance agreement to be entered
into by the Parties which shall set forth the safety data exchange procedures to be followed by the Parties for the collection,
investigation, reporting and exchange of information concerning adverse events.

 

		(mm)	“Products” means the finished pharmaceutical products in commercially saleable
form, as manufactured by ELITE and semi-exclusively and/or exclusively supplied to GLENMARK pursuant to this Agreement as set forth
on Schedule A.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	4

     

    

 

		(nn)	“Purchase Order” means a written, binding purchase order for a certain quantity
of Product properly issued by GLENMARK in accordance with the terms of this Agreement.

 

		(oo)	“Quality Agreement” means a quality agreement to be entered into by the Parties
which will set forth certain obligations of the Parties in relation to the manufacture, packaging, quality control and testing
of the Products in accordance with GMP.

 

		(pp)	“Recall” shall mean a recall, removal, market withdrawal, seizure, or field
correction of Product.

 

		(qq)	“Regulatory Authorities” means any federal, state, local or international regulatory
agency, department, bureau or other governmental entity responsible for regulating the manufacture, use, storage, importation,
transportation, distribution marketing, promotion and sale of pharmaceutical products in the Territory, including the FDA and DEA.

 

		(rr)	“Semi-exclusive” means that ELITE may at its discretion manufacture and supply
products for itself and for third parties

 

		(ss)	“Specifications” means the written methods, formulae, procedures, specifications,
tests (and testing protocols) and standards pertaining to the Products as approved by FDA in the Product’s ANDA and attached
herein as Schedule B, which may be amended from time-to-time by the written agreement of the Parties.

 

		(tt)	“Term” has the meaning given in Article 8.1.

 

		(uu)	“Territory” means the United States of America and its possessions, territories,
protectorates, military bases and commonwealths.

 

		(vv)	“Third Party” means any Person other than GLENMARK or ELITE, or any of their
respective Affiliates.

 

		(ww)	“Trademarks” has the meaning given in Article 4.3(a).

 

		1.2	Interpretation of “Include”. Where the words “include”, “includes”
or “including” are used in this Agreement, they shall mean, respectively, “include without limitation”,
“includes without limitation”, “including but not limited to”, or “including without limitation”.

 

ARTICLE
2 - MARKETING AUTHORIZATIONS

 

		2.1	Subject to the terms of this Agreement, ELITE shall exclusively and/or semi-exclusively, as the
case may be, manufacture, supply, package and label the Products for GLENMARK, and GLENMARK shall have the right to promote, market,
store, distribute and sell the Products in the Territory. ELITE hereby grants to GLENMARK and its Affiliates an exclusive and/or
semi-exclusive right to fully commercialize the Products in the Territory. GLENMARK agrees to exclusively purchase Products it
requires from ELITE.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	5

     

    

 

		2.2	ELITE shall, at its expense, maintain and update the Marketing Authorizations for the Products
as may be required for the Parties to perform their obligations hereunder. ELITE shall be solely responsible for all communications
with the Regulatory Authorities in the Territory relating to any Marketing Authorizations for the Products. ELITE shall provide
GLENMARK with timely notice of any communications from the Regulatory Authorities which may affect ELITE’s right or ability
to supply GLENMARK with the Products.

 

ARTICLE
3 - PAYMENT TERMS

 

		3.1	Transfer Price. ELITE shall sell each Product to GLENMARK at the prices set forth in Schedule
A, which Transfer price shall be inclusive of all costs and expenses associated with the manufacture, supply, packaging, labeling
of the Product to GLENMARK. ELITE shall not offer to sell the semi-exclusive Product to a Third Party at a lower price than that
set forth in Schedule A without first offering to amend Schedule A and sell the Product at such lower price to GLENMARK.

 

		3.2	Upon delivery of the Products to GLENMARK, ELITE shall submit invoices therefore to GLENMARK. GLENMARK
shall pay each undisputed invoice in full within thirty one (31) days of its receipt in full of the Products reflected in the invoice
and the Certificate of Analysis, which Certificate is in a form sufficient for release of the Products. A late payment fee of one
percent (1%) per month may be imposed upon GLENMARK for payments past due, unless Products therein are subject to a quality dispute.
In the event of any inconsistency between an invoice and this Agreement, the terms of this Agreement shall control.

 

		3.3	License Fees. Throughout the Initial Term and Renewal Term, GLENMARK shall pay to ELITE {***}percent
({***}%) of the Gross Profits received from sales of each Product within forty-five (45) days of the end of each calendar
quarter (“License Fees”). Such payment shall additionally include a sales summary for each Product generally in the
format as provided in Schedule C. In no case shall the License Fees for any calendar quarter be negative; provided, however
in the event of a loss in any calendar quarter, the amount of that loss shall be carried forward to subsequent calendar quarters
until the amount of such loss has been fully absorbed.

 

ARTICLE
4 - MANUFACTURING AND SUPPLY; COMMERCIALIZATION

 

		4.1	Supply of Products.

 

		(a)	During the Term of this Agreement, ELITE shall use Commercially Reasonable Efforts to manufacture,
timely supply, package and label for delivery to GLENMARK the Products in accordance with any Purchase Orders issued by GLENMARK
under the terms of this Agreement. ELITE shall manufacture, supply, package and label the Products in compliance with all Laws,
including the GMPs, the Marketing Authorization, the Quality Agreement, and the Specifications (“Manufacturing Requirements”).

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	6

     

    

 

		(b)	ELITE shall manufacture the Products in the Facility and use Commercially Reasonable Efforts to
maintain access to sufficient supplies of raw materials, components and other required resources to perform its obligations under
this Agreement, and meet GLENMARK’s supply requirements for the Products. ELITE shall not manufacture the Products at a site
other than the Facility without first obtaining GLENMARK’s prior written consent, which consent shall not be unreasonably
withheld. ELITE shall be solely responsible for all costs and expenses incurred in connection with the manufacture of the Products
hereunder, including without limitation costs and expenses of personnel, quality control, testing, manufacturing, facilities, equipment,
materials, FDA product fees, FDA establishment fees and government sales, use, excise, property or similar taxes or excises.

 

		(c)	ELITE shall have procedures in place to ensure that the oldest approved inventory of the Products
is distributed first. In addition, each Party shall maintain a tracking system by which the distribution of each lot of the Products
may be readily determined to facilitate its Recall if necessary.

 

		(d)	Transfer Price Adjustments. The Transfer Prices for the Products under Schedule A are valid
through {***}. After {***}, the Transfer Price for Products may be adjusted up or down for changes in the cost of
active pharmaceutical ingredients, annual Generic Drug User Fees (GDUFA fees) proportional allocation, and material changes in
serialization requirements. ELITE shall provide at least thirty (30) days written notice to GLENMARK for any such Transfer Price
adjustments with justifications for any increase.

 

		(e)	The Parties shall enter into a Pharmacovigilance Agreement and Quality Agreement prior to the commencement
of any manufacturing activities under this Agreement. The respective roles and responsibilities for quality assurance personnel
of the Parties in carrying out the transactions pursuant to this Agreement shall be defined and stipulated in the Quality Agreement.
The fully executed Pharmacovigilance Agreement and Quality Agreement are hereby incorporated and made a part of this Agreement
by reference. In the event of any inconsistency between the provisions of the Pharmacovigilance Agreement and the provisions of
this Agreement, the wording of the Pharmacovigilance Agreement shall govern any and all patient safety matters and this Agreement
shall govern all other matters. The Parties hereby acknowledge and agree that in the event of any conflict between the terms of
this Agreement and the terms of the Quality Agreement, this Agreement shall control with respect to all issues (other than with
respect to the allocation of responsibility for quality assurance), and the Quality Agreement shall control with respect to the
allocation of responsibility for quality assurance.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	7

     

    

 

		4.2	Master Production Plan and Purchase Orders. On or before fifteen (15)days prior to the end
of each calendar quarter during the Term, GLENMARK shall deliver to ELITE a master production plan which covers a twelve (12) month
period, which includes three (3) months binding purchase order, and nine (9) months non-binding forecast (the “Master
Production Plan”). The first three months (beginning with the first month following the month in which the Master Production
Plan is due) of each Master Production Plan shall be deemed to be a binding purchase order (the “Binding Forecast”).
Months four (4) through twelve (12) of the Master Production Plan shall be GLENMARK’s non-binding, good faith estimate of
such requirements based on forecasted trade and GLENMARK shall have the ability to adjust the quantities forecast. Unless the Parties
otherwise agree in writing, all firm orders for Product (the “Purchase Order”) placed shall specify: (i) the
type of Product being ordered; (ii) the amount of such Product being requested (which shall be in whole batch size quantities);
and (iii) the requested delivery date which, unless otherwise agreed by ELITE in writing, shall be not less than ninety (90)
days after receipt of the Purchase Order. Each Master Production Plan and accompanying binding Purchase Order shall be deemed to
be automatically accepted unless ELITE notifies GLENMARK of its rejection of the same within five (5) Business Days of receipt.
ELITE may only reject a Purchase Order if a Purchase Order is not consistent with the terms of this Article 4.2 or is not
timely delivered. Once a Purchase Order is accepted by ELITE, ELITE shall be obligated to timely manufacture, supply, package,
label, and have ready for delivery the full quantities of Products set forth in the Purchase Order by the required delivery date
at the Facility. In the event that the terms of any Purchase Order are not consistent with, or attempt to modify, the terms of
this Agreement, the terms of this Agreement shall prevail. If GLENMARK requests changes to any Purchase Order after receipt thereof
by ELITE, ELITE shall use Commercially Reasonable Efforts to comply with such changes.

 

		4.3	Delivery Terms.

 

		(a)	GLENMARK shall provide ELITE packaging specifications and related materials that comply with FDA
requirements and the Parties will finalize all packaging by the time of the first Purchase Order. If requested by GLENMARK, ELITE
shall affix on the Product and/or on the label and/or the packages certain proprietary or registered marks, logos or insignia relating
to the Product in accordance with the directions and specifications given by GLENMARK, along with any other marks, logos or insignia,
as GLENMARK may stipulate from time to time (collectively, “Trademark”). Pursuant to the aforesaid, GLENMARK
hereby grants to ELITE, a non-exclusive, non-transferable, non-assignable and non-sublicensable right to the Trademarks, solely
for the purpose of affixing such Trademarks to the Product in accordance with GLENMARK’s directions and specifications during
the Term. GLENMARK shall have sole approval authority over all Product labeling and packaging specifications of the Products supplied
to GLENMARK pursuant to this Agreement.

 

		(b)	ELITE shall deliver the full quantities of the Products set forth in each Purchase Order (Incoterms
2010 EXW) to GLENMARK or its designee. All Products shall be packaged for shipment in accordance with the packaging specifications
set forth in the Marketing Authorizations and packing instructions reasonably required by GLENMARK.

 

		(c)	Each Products shipment made by ELITE shall be accompanied by and shall include a Certificate of
Analysis for each shipment of the Products manufactured and supplied hereunder. ELITE shall be responsible for all applicable release
testing of the Products in accordance with the Manufacturing Requirements. ELITE shall perform all required in process quality
control tests and quality assurance reviews on the Products, including without limitation, stability testing at its sole cost and
expense. In addition, ELITE shall furnish GLENMARK, along with the first shipment of the Products, ELITE's Material Safety Data
Sheets containing the relevant safety and health information and such other similar information as GLENMARK may reasonably from
time-to-time request in connection therewith.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	8

     

    

 

		(d)	All Products provided to GLENMARK shall have no less than eighty five percent (85%) remaining shelf-life
remaining as per the Product’s ANDA.

 

		(e)	All orders containing at least ninety percent (90%) of the specified amount of Product in a given
Purchase Order shall be deemed satisfied.

 

		4.4	Failure to Supply. ELITE shall notify GLENMARK as promptly as possible, but in no event
later than five (5) Business Days, after ELITE discovers that it will not be able to supply the quantity of Products ordered by
the delivery date specified in a Purchase Order. In such event: (i) ELITE shall cooperate with GLENMARK in taking all actions that
GLENMARK deems reasonably necessary in order to remedy such inability to supply, at ELITE’s expense; and (ii) If ELITE’s
inability to supply continues past twenty (20) days from the required delivery date set forth in the Purchase Order at GLENMARK’s
election, any or all outstanding Purchase Orders relating to such Product may be cancelled and GLENMARK shall have no obligations
with respect to such Purchase Orders. Compliance by ELITE with this Article 4.4 shall not relieve ELITE of any other obligation
or liability under this Agreement. GLENMARK shall otherwise retain all of its rights under this Agreement and/or at law against
ELITE for its failure to deliver all or any portion of the quantity of Products ordered by GLENMARK. If ELITE’s inability
to supply continues past twenty (20) days from the required delivery date set forth in the Purchase Order, GLENMARK may, in its
sole discretion, elect to terminate this Agreement immediately upon written notice to ELITE. With regards to a Binding Forecast
or if ELITE accepted a Purchase Order from GLENMARK, pursuant to the procedures defined in Section 4.2 of this Agreement, then
ELITE shall be responsible for the late charges and any penalties assessed against GLENMARK by its Customers, unless the delay
is attributable to (i) action or controls imposed by the DEA that do not result from ELITE's negligence; or (ii) demonstrable raw
material shortages that are beyond ELITE's control. Late charges and any penalties assessed against ELITE by GLENMARK under this
paragraph are due and payable within thirty (30) days of being invoiced by GLENMARK and, if not timely paid, may be deducted against
amounts owed by GLENMARK to ELITE.

 

		4.5	Samples and Batch Records. ELITE shall prepare and maintain batch records and file samples,
properly stored, for each lot or batch of Products manufactured and shipped hereunder in compliance with all GMPs and Laws in the
Territory.

 

		4.6	Commercialization.

 

		(a)	GLENMARK shall use Commercially Reasonable Efforts to market and sell the Products in the Territory.
All commercial matters regarding the marketing, promotion, sale, offer for sale, pricing or distribution of the Products in the
Territory shall be under the exclusive control of GLENMARK.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	9

     

    

 

		4.7	Change of Specification. No alterations of the Specifications for the Products or other
changes requiring prior approval by the FDA, or Major Changes to the manufacturing process or validated processes, can be made
without the prior written approval of GLENMARK. ELITE shall notify GLENMARK in writing of any proposed alterations for the Specifications
for the Products or any Major Changes to the manufacturing process or validated processes. GLENMARK shall notify ELITE of GLENMARK’s
decision within sixty (60) days of receipt of such proposal from ELITE. If ELITE does not receive GLENMARK’s decision in
writing within sixty (60) days, the alteration of the Specifications or other Major Changes to the manufacturing process or validated
process proposed by ELITE shall be deemed rejected by GLENMARK. In the event that the FDA or any other governmental authority shall
suggest or mandate any change or revision to the Product, such that the Specifications would no longer comply with such suggestion
or mandate, the Parties shall work together in good faith to develop revised Specifications that meet all changes or revisions
suggested or mandated by the FDA or other governmental authority and Schedule B shall be amended in writing to set forth
the new agreed upon Specifications.

 

		4.8	Acceptance of the Product.

 

		(a)	Following receipt of a shipment of Product at the final destination, GLENMARK, or its designee,
shall conduct a visual inspection of the Product and all accompanying documents provided by ELITE, including without limitation,
the Certificate of Analysis, in accordance with its customary procedures. GLENMARK shall advise ELITE, in writing, if it is rejecting
a shipment of Product due to obvious physical damage or obvious packaging defect that are evident upon such visual inspection of
the packaged Product as shipped by ELITE. GLENMARK (and its designees) shall have no obligation to inspect the Product beyond the
visual inspection provided for in this Article 4.8(a).

 

		(b)	In the case of defects other than those obvious defects described in Article 4.8(a), including,
by way of example, any failure of the Product, at the time of delivery, to meet the Manufacturing Requirements and the representations,
warranties and covenants of Article 9.2(f), GLENMARK shall promptly notify ELITE if it becomes aware of such non-obvious
defect(s). Any defect in physical condition of Products delivered by ELITE or Products that do not conform with the Manufacturing
Requirements (as may be in effect from time to time) or the representations, warranties and covenants of Article 9.2(f)
for any reason shall be deemed to be a non-conforming product (“Non-Conforming Product”). GLENMARK, or its designee,
shall have the right to reject any Non-Conforming Product and no failure on the part of GLENMARK, or its designee, or passage of
time shall prejudice GLENMARK’s right to reject or revoke acceptance of Non-Conforming Product. All Non-Conforming Product
shall be returned to ELITE at its sole cost and expense.

 

		(c)	If ELITE confirms the Non-Conforming Product or lab testing pursuant to Article 4.8(d) determines
that the Product is Non-Conforming Product, ELITE shall, at GLENMARK’s election, either replace such Non-Conforming Product
with conforming Product or, refund to GLENMARK, the price paid for such Non-Conforming Product plus any out-of-pocket expense GLENMARK
may have incurred with respect thereto prior to its discovery of the defect, including without limitation shipping, insurance,
recall, market withdrawal, regulatory compliance, returns, destruction, and packaging costs, and in any case, within forty-five
(45) days of confirmation or determination of Non-Conforming Product.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	10

     

    

 

		(d)	If the Parties cannot agree as to whether a delivered quantity of Product is Non-Conforming Product,
then the Parties agree to have the batch in dispute tested and further analyzed by a recognized independent testing laboratory
selected by the Parties. The appointment of such laboratory shall not be unreasonably withheld or delayed by either Party. The
decision of the laboratory shall be in writing and, save for manifest error on the face of the decision, shall be binding on both
Parties. Should said laboratory’s testing determine that the Product is Non-Conforming Product then ELITE will bear the cost
of such testing and comply with the terms of Article 4.8(c). If said Product is determined to have been conforming, then
GLENMARK shall bear all costs of the independent laboratory testing as well as accept the Product shipment and pay for same within
forty-five (45) days of such acceptance.

 

ARTICLE
5 - INSPECTIONS

 

		5.1	Inspections. During the Term of this Agreement and thereafter in the event of a Claim against
either Party regarding use of the Products is threatened or commenced, ELITE shall permit GLENMARK’s representatives to enter
ELITE’s facilities, upon reasonable prior notice (except in the event of a for-cause audit) and during normal business hours,
for the purpose of inspecting the facility and quality control procedures and confirming compliance with all applicable GMPs and
Laws in the Territory, the requirements of the Regulatory Authorities in the Territory, the Quality Agreement and this Agreement.
If during any such inspection GLENMARK discovers any instances in which ELITE has not complied with the foregoing, then ELITE shall
promptly provide to GLENMARK a written plan for correcting such deficiencies, including a proposed timetable for implementing such
corrections, and shall ensure that such deficiencies are corrected, at ELITE’s sole expense, as soon as reasonably practicable.
ELITE agrees to provide GLENMARK with copies of all: (i) reasonably requested documentation in its possession relating to the manufacture
of Product, Specifications, compliance with quality assurance standards, raw material vendors and manufacturing processes; and
(ii) U.S. and international regulatory approvals, regulatory inspections of the manufacturing process, facilities and documentation,
and other communications with Regulatory Authorities related to the Product; however ELITE shall not be required to provide copies
to GLENMARK of ELITE’s proprietary information and ELITE shall only be required to allow GLENMARK to inspect such proprietary
information such as batch records at ELITE’s site and under ELITE’s supervision. Notwithstanding the provision of this
Article 5.1, GLENMARK shall have no obligation or be deemed to have an obligation to inspect ELITE’s facilities.

 

		5.2	Regulatory Authority Inspections. ELITE shall permit any Regulatory Authority to
inspect the facility used to manufacture the Products and all associated records to the full extent permitted by applicable Law
(“Regulatory Inspection”). ELITE shall notify GLENMARK within forty-eight (48) hours of becoming aware of any
planned or actual Regulatory Inspection. ELITE agrees to reasonably cooperate with the applicable Regulatory Authority in connection
with such audits. ELITE shall notify GLENMARK prior to the commencement of any meetings with, or inspection activity by, any Regulatory
Authority, unless such inspection activity is an unannounced inspection. Further, ELITE shall provide a reasonable description
to GLENMARK of any such governmental inquiries, notifications or inspections promptly (but in no event later than two (2) calendar
days) after such visit or inquiry. ELITE shall furnish to GLENMARK: (i) within two (2) calendar days after receipt, any report
or correspondence issued by the Regulatory Authority in connection with such visit or inquiry, including but not limited to, any
FDA Form 483, establishment inspection report, or warning letter; and (ii) copies of any and all responses or explanations to any
Regulatory Authority relating to items set forth above prior to the submission of such responses or explanations to any Regulatory
Authority by ELITE for comment, which comments shall be taken into consideration by ELITE in good faith. ELITE shall also provide
GLENMARK with a copy of all final responses.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	11

     

    

 

ARTICLE
6 - RECORDS

 

		6.1	Records. ELITE and GLENMARK shall maintain all records necessary to comply with all applicable
Laws in the Territory relating to the performance of their respective obligations under this Agreement. ELITE shall also maintain,
or cause to be maintained (i) all manufacturing records, standard operating procedures, validation records, equipment log books,
batch records, laboratory notebooks and all raw data relating to the manufacturing of the Products, and (ii) such other records
as GLENMARK may reasonably require in order to ensure compliance by ELITE with the terms of this Agreement. All such records shall
be maintained for such period as may be required pursuant to the applicable Laws.

 

		6.2	Inspection of ELITE Books and Records. During the Term of this Agreement, and thereafter
for the greater of (i) the period stipulated by the Laws in the Territory, and (ii) two (2) years from the expiration of the last
Products manufactured, ELITE agrees that GLENMARK, at reasonable times upon reasonable prior notice, may inspect the research and
development books and records of ELITE pertaining to ELITE’s obligations under this Agreement for purposes of ensuring compliance
with the terms of this Agreement.

 

		6.3	Inspection of GLENMARK Books and
Records. GLENMARK shall keep, and shall require its Affiliates to maintain, in connection with the handling, sale, and distribution
of the Product hereunder, books and records necessary to allow the accurate calculation, consistent with GAAP, of the amounts
due to ELITE, the reporting obligations contemplated herein, and compliance with the terms of this Agreement, and GLENMARK shall
maintain such books and records for a period of at least two (2) years after the end of the calendar year in which they were generated,
or for such longer period as may be required by Applicable Law. Upon at least thirty (30) days prior written notice of each calendar
year, ELITE, at its expense, shall have the right to have an independent public accounting or auditing firm, reasonably acceptable
to GLENMARK, obtain access to such books and records as may be reasonably necessary to determine or verify the amount of payments
due under this Agreement and compliance with the obligations hereof; provided, however, that this right may not be exercised more
than once in any calendar year. Such accounting firm shall conduct such examination, and GLENMARK shall make such books and records
available, during normal business hours at the facility(ies) where such books and records are customarily maintained. Each such
examination shall be limited to pertinent books and records for any year ending not more than twenty-four (24) months prior to
the date of request, except that ELITE shall not be permitted to audit the same period of time more than once. The independent
accounting firm will prepare and provide to each Party a written report stating whether the reports submitted and amounts paid
are correct or incorrect and the amounts of any discrepancies. The conclusions of such accounting firm shall be final and binding
on the Parties absent demonstrable error. If there was an underpayment by GLENMARK hereunder, GLENMARK shall promptly (but in
no event later than thirty (30) days after its receipt of the independent auditor’s report so concluding) make payment to
ELITE of any shortfall by wire transfer in U.S. dollars, plus interest on the amount of such shortfall calculated at the lesser
of (a) five percent (5%) per annum, or (b) the maximum rate permitted by law from the date such payment should have been made
to the date the shortfall is paid. If there was an overpayment by GLENMARK hereunder, ELITE shall promptly (but in no event later
than thirty (30) days after ELITE’s receipt of the independent auditor’s report so concluding) refund to GLENMARK
the excess amount by wire transfer in U.S. dollars. All costs of the audit, including the expenses of the independent accounting
firm, shall be borne by ELITE unless the underpayment by GLENMARK results in a cumulative discrepancy during any calendar year
in excess of the greater of (i) ten percent (10%) of the total amount reported to ELITE for that period or (ii) one hundred thousand
dollars ($100,000.00), in which case all reasonable and documented costs of the audit, including the expenses of the independent
accounting firm, shall be borne and promptly paid by GLENMARK. ELITE shall ensure that the independent public accountant or auditor
maintains the confidentiality of GLENMARK’s Confidential Information on terms no less restrictive than those set forth in
this Agreement.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	12

     

    

 

		6.4	Annual Reports. ELITE shall provide Glenmark
in a timely manner copies of ELITE's annual reports to the FDA or any other Regulatory Authority with respect to the Products.

 

ARTICLE
7 - RECALLS

 

		7.1	Notification of Recall. If any Regulatory Authority or other governmental agency issues
or requests a Recall or takes similar action in connection with a Product in the Territory, or if GLENMARK reasonably determines
after consultation with ELITE that an event has occurred which may result in the need for a Recall, the Party notified of or wishing
to implement such Recall shall, within forty-eight (48) hours (regardless of weekday, weekend or holiday), advise the other Party
thereof by telephone or facsimile, after which the Parties shall promptly discuss and work together to effect an appropriate course
of action. ELITE shall be responsible for notifying the Regulatory Authorities in the Territory of any voluntary Recall and implementing
any Recalls. GLENMARK shall fully cooperate with ELITE to fully implement any Recall. ELITE agrees to forward to the GLENMARK a
copy of any field communication associated with the Products that it plans to issue before such communication is issued or sent
to any governmental agency. ELITE will maintain complete and accurate records of any activities conducted with respect to any Recall
for such period as may be required by Law. Following any Recall, ELITE will review all of its procedures as impacted by the identified
root cause in the associated investigation, and will revise such procedures, as necessary, to correct the cause of such Recall
subject to the change control requirements set forth in the Quality Agreement. ELITE will provide GLENMARK with such information
regarding such review and revisions as GLENMARK may request and ELITE shall provide GLENMARK the right to approve, reject or request
modifications to the proposed changes.

 

		7.2	Recall Expenses. If a Recall results from the acts or omissions of one Party, then such
Party shall bear the full expenses of both Parties incurred in the Recall. If a Recall is partially caused by the actions or omissions
of both Parties, then each Party shall be responsible for its proportionate share of the Recall expenses based on its proportionate
share of causation. Recall expenses include the expenses of notification, shipping, return, replacement (if possible), customer
fees and penalties, and destruction of recalled Products (including Products which cannot be shipped due to the condition causing
the Recall). The Parties shall discuss in good faith and agree on the scope and costs of Recall, if practicable, prior to enforcement
of the Recall.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	13

     

    

 

		7.3	Notice of Failure to Meet Specifications. If ELITE discovers that there is a potential that
any batch or lot of the Products already delivered to GLENMARK may fail to conform to the Specifications, then ELITE shall notify
GLENMARK within twenty-four (24) hours (or one (1) business day), of such determination of failure to meet the Specifications and
of the nature thereof in detail, including, but not limited to, supplying GLENMARK with all investigatory reports, data and communications,
out-of-specification reports and data and the results of all outside laboratory testing and conclusions, if any. ELITE shall investigate
all such failures promptly, and at its sole expense, cooperate with GLENMARK in determining the cause for the failure and a corrective
action to prevent future failures.

 

ARTICLE
8 - TERM & TERMINATION

 

		8.1	Term. This Agreement shall commence upon the Effective Date, and, unless terminated earlier
in accordance with the provisions hereof, shall continue for a period of three (3) years from the Effective Date (“Initial
Term”). Unless earlier terminated pursuant to this Agreement, the Initial Term shall automatically be extended for successive
one (1) year periods (“Renewal Term”) unless at least one hundred eight (180) days before the expiration of
the then current Term, a Party gives written notice to the other Party that it does not wish to extend the Agreement. The Initial
Term and all Renewal Term (if any) are collectively referred to as the “Term.”

 

		8.2	Termination. If any one or more of the following events of default shall occur, then this
Agreement may be terminated as set forth herein:

 

		(a)	if a Party files a petition in bankruptcy or is adjudged as bankrupt, or a petition in bankruptcy
is filed against it and is not dismissed within sixty (60) days, or it becomes insolvent, takes advantage of legislation for creditor
relief, has a receiver or receiver-manager appointed in relation to its assets, or discontinues its business, then the other Party
may terminate this Agreement upon delivering written notice of termination;

 

		(b)	if a Party hereto violates or fails to perform any of its material undertakings, agreements, covenants
or obligations under this Agreement (excluding matters otherwise specifically addressed with a termination right elsewhere in this
Agreement) and the failure is not remedied within thirty (30) days after written notice from the non-defaulting Party, then the
non-defaulting Party may terminate this Agreement upon delivering written notice of termination to the breaching Party; provided
that if the breaching Party is diligently pursuing in good faith the remedy of the breach at the expiration of such thirty (30)
day cure period, then such thirty (30) day cure period shall be extended as reasonably required to effect the cure;

 

		(c)	if a Party hereto willfully or fraudulently misrepresents any fact, information or report disclosed
pursuant to this Agreement and such misrepresentation is not cured or remedied within thirty (30) days after the receipt of written
notice thereof by the non-defaulting Party, then the other Party may terminate this Agreement upon delivering written notice of
termination;

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	14

     

    

 

		(d)	if a court of competent jurisdiction makes a final determination that the marketing and sale of
a Product in the Territory infringes the patent or other Intellectual Property Rights in the Territory of a third party and enjoins
the marketing and sale of the Product in the Territory, and if all rights to appeal have been exhausted or expired, then GLENMARK
may, upon delivering written notice to ELITE, terminate this Agreement with respect to such Product;

 

		(e)	if GLENMARK decides to discontinue the marketing and selling of a Product for any reason, including
its economic viability or changes in market or regulatory conditions, then GLENMARK may terminate this Agreement with respect to
such Product without penalty upon delivering written notice to ELITE not less than three (3) months prior to termination; and

 

		(f)	by ELITE, on a Product by Product basis, if any time after the first twelve (12) months from the
first commercial sale, the average License Fee paid by Glenmark is less than {***} dollars (US${***}) for a{***}
six ({***} ) month sales period for that Product.

 

		8.3	Other Termination Rights. In addition to Article 8.2, (i) either Party may terminate
this Agreement pursuant to Articles 13.3 (Assignment without Consent) and 13.5 (Force Majeure), and (ii) GLENMARK
may terminate this Agreement pursuant to Article 4.4 (Failure to Supply) and Article 9.2(c) (Debarred), and (iii)
ELITE may terminate this Agreement pursuant to Article 9.3(c) (Debarred).

 

		8.4	Effect of Termination. Upon termination or expiration of this Agreement, the provisions
of this Agreement shall continue to apply with respect to the Parties’ respective rights and obligations in relation to any
Purchase Order made prior to such termination, including without limitation ELITE’s obligation to manufacture, release and
deliver Products to GLENMARK, and GLENMARK’s obligation to make payment for such Products. If this Agreement is terminated
while GLENMARK is still in possession of Products (“Remaining Products”), ELITE hereby grants GLENMARK and its
Affiliates a license to promote, market, distribute and sell the Remaining Products in the Territory, subject to the License Fees
in Article 3.3.

 

		8.5	Survival. The expiration or earlier termination of this Agreement shall not relieve either
Party hereto from any obligations which accrued prior to such expiration or earlier termination, and shall not destroy or diminish
the binding force and effect of any of the terms and conditions of this Agreement that expressly or by implication come into or
continue in effect on or after termination or expiration, including ARTICLE 1 - , ARTICLE 5 - , ARTICLE 6 - , ARTICLE 7 - ,
Section 8.4, ARTICLE 9 - , ARTICLE 11 - , ARTICLE 12 - , Sections 13.6, and 13.7. Further, the provisions
from the Original Agreement that were deemed to survive the termination or expiration of that Agreement shall further survive.

 

ARTICLE
9 - REPRESENTATIONS & WARRANTIES

 

		9.1	Representations and Warranties. Each Party represents and warrants to the other Party as
follows, which representations and warranties shall be true as at the date hereof and throughout the Term of this Agreement:

 

		(a)	it has full corporate power and authority and has taken all corporate action necessary to enter
into and perform this Agreement; and

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	15

     

    

 

		(b)	this Agreement is its legal, valid and binding obligation, enforceable in accordance with the terms
and conditions hereof.

 

		9.2	ELITE General and Supply Warranties. ELITE represents and warrants to GLENMARK as follows:

 

		(a)	No Other Agreements. No contracts, commitments or agreements of any nature exist, and none
will be entered into during the Term of this Agreement, that impair or inhibit the ability of ELITE to perform its obligations
hereunder.

 

		(b)	No Lawsuits. As of the date hereof there have not been any Claims, lawsuits, arbitrations,
legal or administrative or regulatory proceedings, charges, or complaints or investigations, by any third party or government authority
threatened, commenced, pending or proceeding against ELITE, and ELITE has not received any notice thereof, which could prevent
ELITE from complying with its material obligations under this Agreement.

 

		(c)	Debarred. Neither ELITE nor any of its officers, directors, or employees or consultants
performing services under this Agreement has been or is: (1) an individual who has been debarred by the FDA pursuant to 21 U.S.C.
§ 335a(a) or (b) (“Debarred Individual”) from providing services in any capacity to a person that has an
approved or pending drug product application with FDA, or an employer, employee, or partner of such a Debarred Individual; or (2)
a corporation, partnership or association that has been debarred by FDA pursuant to 21 U.S.C. § 335a(a) or (b) (“Debarred
Entity”) from submitting or assisting in the submission of an NDA, or an employee, partner, shareholder, member, subsidiary,
or affiliate of a Debarred Entity; or (3) an employer, employee or partner of an individual convicted within the last five years
for crimes described in subsections (a) or (b) of Section 306 of the FDCA. If and when ELITE becomes aware of any fact that makes
or gives rise to make this representation and warranty untrue, ELITE shall immediately notify GLENMARK in writing and any such
breach may result in immediate termination of this Agreement by GLENMARK.

 

		(d)	Non-Infringement.

 

		(i)	ELITE’s performance of its obligations hereunder does not and will not infringe any intellectual
property rights of a third party.

 

		(ii)	No patents, patent applications if issued, or any other proprietary rights of any third party would
be infringed by the manufacture, use or sale of the Product and ELITE shall indemnify, defend and hold harmless GLENMARK and its
Affiliates against any and all such infringement claims, demands, actions, losses, damages, fines, penalties, costs and expenses
(including reasonable attorneys’ fees). The indemnification obligation of ELITE shall include Third Party patents issued
after the Effective Date.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	16

     

    

 

		(e)	Facility. The Facility is in compliance with all Laws, including without limitation GMP,
and that there are no, nor have been any, citations or adverse conditions of a material nature noted in any inspection of the site
which would cause the Product to be misbranded or adulterated. It has and shall maintain sufficient knowledge and experience and
adequate production facility(s), equipment and processes to produce the Product and perform its obligations under this Agreement
in compliance with all Laws.

 

		(f)	Products Supply. ELITE warrants, represents and covenants to GLENMARK that all Products
delivered to GLENMARK hereunder shall:

 

		(i)	comply with the Specifications;

 

		(ii)	comply with the applicable Purchase Order;

 

		(iii)	be manufactured, tested, packaged, labeled, stored, handled and delivered by ELITE in accordance
with (i) the terms of this Agreement, including the Specifications, and the Quality Agreement, (ii) the requirements of the Marketing
Authorization, and (iii) all applicable GMPs and Laws in the Territory, including regulations set forth by the DEA;

 

		(iv)	be manufactured at the Facility approved by the Regulatory Authorities in the Territory;

 

		(v)	not be adulterated or misbranded under any applicable Laws in the Territory;

 

		(vi)	have at least eighty-five percent (85%) of the Product’s shelf-life remaining at the time
of delivery; and

 

		(vii)	be free of all liens, security interests, and other claims of any nature and free from defects
in material, manufacturing and workmanship for the shelf-life of the Products.

 

		(g)	be manufactured, supplied, packaged, labeled and delivered in compliance with all serialization
and aggregation requirements set forth in the Drug Supply Chain Security Act (DSCSA)Marketing Authorizations. ELITE warrants, represents
and covenants to GLENMARK that (i) all Marketing Authorizations have been obtained as necessary to permit GLENMARK to manufacture,
use, store, import, transport and sell the Product in the Territory pursuant to the terms of this Agreement and (ii) ELITE shall
maintain all necessary Marketing Authorizations in good standing to permit GLENMARK to manufacture, use, store, import, transport
and sell the Product in the Territory pursuant to the terms of this Agreement.

 

		(h)	It is and shall at all times relevant to this Agreement be in full compliance with all applicable
Laws relating or impacting in the performance of ELITE’s duties and obligations under this Agreement, including but not limited
to, those rules, regulations, and/or guidance promulgated or issued by the FDA, the Centers for Medicare & Medicaid Services,
the U.S. Department of Health and Human Services Office of Inspector General the U.S. Drug Enforcement Agency, the U.S. Department
of Justice, as well as any applicable environmental requirements and all serialization and aggregation requirements set forth in
the Drug Supply Chain Security Act.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	17

     

    

 

		(i)	Subject to DEA quotas, it has access to sufficient supplies of raw materials, components and other
required resources to perform the services required under this Agreement, and shall exercise commercially reasonable and diligent
efforts to maintain access to sufficient supplies without interruption during the Term.

 

		9.3	GLENMARK General Warranties. GLENMARK represents and warrants to ELITE that:

 

		(a)	No Other Agreements. No contracts, commitments or agreements of any nature exist, and GLENMARK
covenants that none will be entered into during the Term of this Agreement that impair or inhibit the ability of GLENMARK to perform
its obligations hereunder.

 

		(b)	No Lawsuits. As of the date hereof there have not been any Claims, lawsuits, arbitrations,
legal or administrative or regulatory proceedings, charges, or complaints or investigations by any third party or government authority
threatened, commenced, pending or proceeding against GLENMARK, and GLENMARK has not received any notice thereof, which could prevent
GLENMARK from complying with its material obligations under this Agreement.

 

		(c)	Debarred. Neither GLENMARK nor any of its officers, directors, or employees or consultants
performing services under this Agreement has been or is: (1) a Debarred Individual or an employer, employee, or partner of such
a Debarred Individual; or (2) a Debarred Entity, or an employee, partner, shareholder, member, subsidiary, or affiliate of a Debarred
Entity; or (3) an employer, employee or partner of an individual convicted within the last five years for crimes described in subsections
(a) or (b) of Section 306 of the FDCA. If and when GLENMARK becomes aware of any fact that makes or gives rise to make this representation
and warranty untrue, GLENMARK shall immediately notify ELITE in writing and any such breach may result in immediate termination
of this Agreement by ELITE.

 

		(d)	It is and shall at all times relevant to this Agreement be in full compliance with all applicable
Laws relating or impacting in the performance of GLENMARK’s duties and obligations under this Agreement, including, to the
extent applicable, but not limited to, those rules, regulations, and/or guidance promulgated or issued by the FDA, the Centers
for Medicare & Medicaid Services, the U.S. Department of Health and Human Services Office of Inspector General the U.S. Drug
Enforcement Agency, the U.S. Department of Justice, as well as any applicable environmental requirements and all applicable requirements
set forth in the Drug Supply Chain Security Act.

 

		9.4	Disclaimer. EXCEPT FOR THE WARRANTIES AND REPRESENTATIONS PROVIDED OR REFERENCED IN THIS
AGREEMENT, THE PARTIES MAKE NO OTHER WARRANTIES OR REPRESENTATIONS TO EACH OTHER, EXPRESS OR IMPLIED, INCLUDING THOSE WITH RESPECT
TO THE PRODUCTS, WHETHER STATUTORY OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ALL OTHER WARRANTIES, INCLUDING ANY IMPLIED
WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	18

     

    

 

ARTICLE
10 - COVENANTS

 

		10.1	Compliance. Each Party shall perform its obligations under this Agreement in strict compliance
with all applicable GMPs and Laws in the Territory, and all applicable licenses, governmental permits or applications in the Territory.

 

		10.2	Permits and Licenses. Each Party shall throughout the Term of this Agreement obtain and
maintain any and all licenses, permits, orders, applications and consents (including facility licenses and permits) required by
the Regulatory Authorities in the Territory, and all applicable Laws, regulations and GMPs necessary or required to perform its
obligations under this Agreement.

 

ARTICLE
11 - INDEMNIFICATION & INSURANCE

 

		11.1	Indemnification of ELITE. GLENMARK shall defend, indemnify and hold harmless ELITE, its
Affiliates and their respective officers, directors, employees, agents and representatives from and against all Losses from any
Third-Party Claim directly resulting from:

 

		(a)	any breach of any obligations, actions, or representations made by GLENMARK under this Agreement;
and

 

		(b)	any grossly negligent or intentionally wrongful act or omission of GLENMARK or of any person acting
on GLENMARK’s behalf, with authorization, when the wrongful act or omission occurred in performance of GLENMARK’s obligations
under this Agreement;

 

provided, however, that the
foregoing indemnification obligations shall not apply to the extent such Losses are caused by an act or omission for which ELITE
is contributorily negligent and/or otherwise required to indemnify GLENMARK under Article 11.2.

 

		11.2	Indemnification of GLENMARK. ELITE shall defend, indemnify and hold harmless GLENMARK, its
Affiliates and their respective officers, directors, employees, agents and representatives from and against all Losses from any
Third-Party Claim directly resulting from:

 

		(a)	any breach of any obligations, actions, or representations made by ELITE under this Agreement;

 

		(b)	any infringement or claim of infringement of any patent, trademark or other intellectual property
rights based on the manufacture and release of the Product furnished under the provisions of this Agreement;

 

		(c)	personal injury (including death) or property damage relating to or arising out of any use, distribution
or sale of the Products by GLENMARK or its Affiliates to the extent that such Loss was the result of the Product not being manufactured
to meet the Manufacturing Requirements; and

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	19

     

    

 

		(d)	any grossly negligent or intentionally wrongful act or omission of ELITE or of any person acting
on ELITE’s behalf, with authorization, when the wrongful act or omission occurred in performance of ELITE’ obligations
under this Agreement;

 

provided, however, that the
foregoing indemnification obligations shall not apply to the extent such Losses are caused by an act or omission for which GLENMARK
is required to indemnify ELITE under Article 11.1. ELITE shall also indemnify GLENMARK for any damages arising from any
interruption in supply of the Products to GLENMARK occasioned by ELITE’s commitments, contractual or otherwise, with a Third
Party subject to Article 4.4.

 

		11.3	Indemnification Procedure. Any Party entitled to indemnification hereunder (the “Indemnitee”)
shall notify the indemnifying Party (the “Indemnitor”) promptly of any claim threatened or commenced against
the Indemnitee. The Indemnitor shall assume control and direct the defense, investigation and handling of the claim for and on
behalf of the Indemnitee, provided, however that the Indemnitor shall not settle or consent to judgment without the Indemnitee’s
approval, which approval shall not to be unreasonably withheld. The Indemnitee shall cooperate with the Indemnitor, and may participate,
at the Indemnitee’s expense, in the defense of such claim. If the Indemnitor fails to assume control of the defense of any
claim, or, having elected to assume control, thereafter fails to diligently defend the claim, the Indemnitee shall, without limitation
to the Indemnitor’s obligations hereunder, be entitled to contest, settle or pay the amount of the claim, and the Indemnitor
shall be bound by the results obtained by the Indemnitee with respect to the claim.

 

		11.4	Insurance. Each Party hereby represents to the other that it has, and during the Initial
Term and any Renewal Term and for three (3) years after termination or expiration of this Agreement, will maintain, products liability
insurance coverage of not less than US {***} dollars (${***}) in the aggregate. For the sake of clarity, should ELITE
increase its product liability insurance coverage beyond this amount, the new levels shall automatically apply to this Agreement.
Upon the request of the other Party hereto, the insured Party shall furnish the other Party with a certificate of insurance evidencing
such coverage and stating that such insurance shall not be cancelled, materially amended or allowed to lapse without at least thirty
(30) days prior written notice to the other Party hereto. Each Party shall list the other Party as an additional insured on such
Party's applicable insurance coverage. Each Party shall provide the certificate of insurance within ten (10) days of its receipt
of a request for proof of insurance.

 

		11.5	Survival. The obligations set forth in this ARTICLE 11 - shall survive the termination
of this Agreement and remain in full force and effect for an indefinite period after termination in relation to any claim based
on events which occur during the term hereof.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	20

     

    

 

ARTICLE
12 - CONFIDENTIALITY

 

		12.1	Confidentiality. During the Term of this Agreement and for five (5) years thereafter, each
Party shall maintain in strict confidence the Confidential Information (as defined below) of the other Party. Each Party shall
not use the Confidential Information of the other Party for any purpose other than the purposes expressly permitted by this Agreement,
and shall not disclose such Confidential Information to any third party (including in connection with any publications, presentations
or other disclosures) except to its employees, agents or advisors (“Representatives”) who have a need to know
such Confidential Information to perform such Party’s obligations under this Agreement. Each Party shall ensure that any
Representative to whom it discloses the other Party’s Confidential Information is informed of the confidential nature of
and duty not to disclose the information, and is obligated under written obligation to maintain the confidentiality thereof on
terms at least as restrictive as those set forth herein. Each Party shall be responsible for any breach of this Agreement by its
Representatives, which shall be considered a breach by such Party. Under no circumstances shall the receiving Party use the disclosing
Party’s Confidential Information for its own commercial advantage to the detriment of the disclosing Party. Each Party may
disclose such of the Confidential Information of the other Party as may be required by the order of a court of competent jurisdiction
or by any governmental authority having jurisdiction, provided that prior to any such disclosure the Party required to disclose
shall, to the extent permitted by Law, notify the other Party prior to disclosing any Confidential Information and provide such
other Party with a reasonable opportunity to contest or limit the scope of the required disclosure and obtain any protective orders
as may be appropriate. In the event the disclosure is nonetheless compelled, the Party making the disclosure shall only disclose
the information to the extent required to comply with the Law. Upon termination or expiration of this Agreement, or upon request,
a Party shall destroy or return all Confidential Information of the other Party and certify in writing that such return (or destruction)
has been completed; provided, however, that each Party shall be entitled to retain one archival copy of such Confidential Information
solely for purposes of monitoring such Party’s compliance with its obligations under this ARTICLE 12 - .

 

		12.2	Definition. “Confidential Information” means all proprietary technical
information, marketing, business and financial information, scientific data, information, whether or not labeled “Confidential”,
and all tangible and intangible embodiments and oral disclosures thereof of any kind whatsoever, and all other materials which
a disclosing Party treats confidentially that relates to a Product or the business of a Party and is disclosed or developed under
or in connection with this Agreement. Confidential Information shall not include any information which the receiving Party can
show by competent proof:

 

		(a)	was known to or in the possession of the receiving Party prior to the date of its actual receipt
from the disclosing Party;

 

		(b)	is readily available to the public other than through the fault of the receiving Party;

 

		(c)	was disclosed by a third party not under an obligation of confidentiality to the disclosing Party;
or

 

		(d)	is subsequently independently developed by the receiving Party without use of the Confidential
Information as demonstrated by competent written records.

 

		12.3	Injunctive Relief. The Parties acknowledge that any breach of this ARTICLE 12 - 
may constitute irreparable harm, and that the non-breaching Party shall be entitled to seek specific performance or injunctive
relief to enforce this ARTICLE 12 -  in addition to whatever remedies such Party may otherwise be entitled to at law or
in equity, without the necessity of posting bond or any other security.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	21

     

    

 

		12.4	No Publicity. Except as required by law, neither Party shall originate any publicity,
news release or other public announcements, written or oral, whether to the public press, to stockholders, or otherwise, relating
to this Agreement, any amendment hereto, performance hereunder or the existence of an arrangement between the Parties without the
prior written approval of the other Party, which approval shall not be unreasonably withheld. Nothing in the provision shall be
deemed to prevent a Party from making such disclosures or announcements that are legally required of such Party; provided
that in any event the non-disclosing Party shall have the right to review any such disclosure and revise such disclosure to the
extent it relates to the use of the non-disclosing Party’s name or Confidential Information. No Party shall, without the
prior written consent of the affected Party, use in advertising, publicity, or otherwise, the name, trademark, logo, symbol, or
other image of the affected Party without the other Party’s prior written consent.

 

ARTICLE
13 - MISCELLANEOUS

 

		13.1	Notices. Any notice or other document required or permitted to be given pursuant to this
Agreement shall be in writing and shall be delivered by personally by hand; by courier; by prepaid certified mail, return receipt
requested; or by email, in each case addressed to the Party to whom it is to be given at the address set forth below or at such
other address as the Party to whom such notice is to be given shall have last notified the other Party in accordance with the provisions
of this section:

 

	 	In the case of ELITE at:	Glenmark Pharmaceuticals, Inc., USA
	 	 	750 Corporate Drive 
	 	 	Mahwah, NJ 07430
	 	 	Attention: President
	 	 	 
	 	And in the case of GLENMARK at:	Elite Pharmaceuticals Inc. 
	 	 	165 Ludlow Avenue
	 	 	Northvale, NJ 07647
	 	 	Attention: CEO

 

Any such notice
or other document shall:

 

		(i)	if delivered by hand, courier, or email be deemed to have been given and received at the place
of receipt on the date of delivery, provided that if delivery is other than during business hours (9:00 a.m. to 5:00 p.m.,
local time) on a Business Day in the place of receipt, such notice shall be deemed to have been given and received at the place
of receipt on the first Business Day thereafter; and

 

		(ii)	if mailed, be deemed to have been given and received at the place of receipt on the earlier of
the date of actual receipt and three (3) Business Days after the date of mailing. In the event of postal disruption, such
notices or documents must be delivered by means other than by mail.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	22

     

    

 

		13.2	Relationship of the Parties. The relationship of the Parties is that of independent contractors.
Nothing in this Agreement shall be deemed or construed to constitute or create between the Parties hereto a partnership, joint
venture, agency, or other relationship other than as expressly set forth herein. This Agreement does not constitute any one Party
hereto as the agent or legal representative of the other Party for any purpose whatsoever. Neither of the Parties grants to the
other any right or authority to assume or create any obligation or responsibility, express or implied, on behalf of it or in its
name in any manner whatsoever, unless otherwise agreed to in writing by the other Party.

 

		13.3	Inurement & Assignment. This Agreement shall be binding upon and inure to the benefit
of the Parties hereto and their respective successors and permitted assigns. Except as otherwise expressly provided herein, neither
Party may assign or transfer it rights or obligations under this Agreement, in whole or in part, without the prior written consent
of the other Party. Notwithstanding the foregoing, both GLENMARK and ELITE shall be entitled to assign its rights and performance
of its obligations under this Agreement to any Affiliate or to the acquirer of all or substantially all of the business or assets
to which this Agreement relates (whether by stock sale, asset sale, merger, consolidation or otherwise), provided that the assigning
Party remains fully responsible for the performance of the obligations of its Affiliates under this Agreement. Any assignment or
transfer by a Party other than in accordance with the terms hereof shall be void and shall entitle the other Party to terminate
this Agreement.

 

		13.4	No Waiver; Remedies. No Party to this Agreement shall be deemed or taken to have waived
any provision of this Agreement unless such waiver is in writing, and then such waiver shall be limited to the circumstances set
forth in such written waiver. No failure or delay on the part of a Party in exercising any right, power or remedy shall operate
as a waiver thereof, nor shall any single or partial exercise of any such right, power or remedy preclude any other or further
exercise thereof or the exercise of any other right, power or remedy. All remedies provided for hereunder shall be cumulative of
and in addition to any and all other remedies, at law or in equity, which any Party may have, and the exercise of any one or more
of such remedies shall not preclude the exercise of any others.

 

		13.5	Force Majeure. If either Party is prevented from complying, either totally or in part, with
any of the terms or provisions of this Agreement by reason of force majeure, including fire, flood, earthquake, storm, general
strike, lockout, riot, war, terrorism, rebellion, accident, acts of God and/or any other cause or externally induced similar casualty
beyond its reasonable control and without the fault or negligence of either Party(a “Force Majeure Event”),
then, upon written notice by the Party liable to perform to the other Party, the requirements of this Agreement or such of its
provisions as may be affected, and to the extent so affected, shall be suspended during the period of such disability, provided
that the Party asserting force majeure shall bear the burden of establishing the existence of such Force Majeure Event by clear
and convincing evidence, and provided further that the Party prevented from complying shall use its best efforts to remove
such disability, and shall continue performance with the utmost dispatch whenever such causes are removed, and shall notify the
other Party of the Force Majeure Event not more than five (5) Business Days from the time of the event and state the nature of
the Force Majeure Event, its anticipated duration and any action being taken to avoid or minimize its effect. The suspension of
performance shall be of no greater scope and no longer duration than is reasonably required. When such circumstances arise, the
Parties shall discuss what, if any, modification of the terms of this Agreement may be required in order to arrive at an equitable
solution. Notwithstanding the foregoing, if a Force Majeure Event shall continue for a period of longer than three (3) consecutive
months or one hundred and twenty (120) days in any twelve (12) month period, then the Party unaffected by such event may terminate
this Agreement immediately upon giving written notice of termination to the other Party. Notwithstanding any provision contained
herein, any action taken by a Regulatory Authority as a result of a Party’s negligence or willful misconduct shall not constitute
a Force Majeure Event under this Article 13.5.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	23

     

    

 

		13.6	Dispute Resolution. The Parties recognize that disputes as to certain matters may from time
to time arise which relate to a Party's rights and/or obligations under this Agreement. It is the objective of the Parties to establish
procedures to facilitate the resolution of such disputes in an expedient manner by mutual cooperation and without resort to litigation.
To accomplish this objective, the Parties agree to follow the procedures set forth in this Article 13.6 if and when such
a dispute arises between the Parties arises. Notwithstanding the provisions of this Article 13.6 however, nothing herein
contained shall preclude a Party from seeking equitable remedies in any court of competent jurisdiction as set forth in Article
13.7 hereof. If any controversy, dispute or claim arises between the Parties relating to the interpretation, breach, performance,
enforcement, termination or validity of this Agreement and the Parties cannot resolve the dispute within thirty (30) days of a
written request by one Party to any other Party, the Parties agree to hold a meeting, attended by the Chief Executive Officer or
President, or a Vice President designated by him/her, of each Party, to attempt in good faith to negotiate a resolution of the
dispute prior to pursuing other available remedies. If, within thirty (30) days after such written request, the Parties have not
succeeded in negotiating a resolution of the dispute, the Party may seek any other remedies available to it in at law or in equity.

 

		13.7	Governing Law & Venue. This Agreement shall be governed by, and construed in accordance
with, the laws of the State of New York, without giving effect to any choice of law or conflict of law rules or provisions that
would cause the application of the laws of any jurisdiction other than the State of New York. Each Party hereby irrevocably submits
to the exclusive jurisdiction of any federal or state court in New York, NY for the purposes of any suit, action or other proceeding
arising out of this Agreement or any transaction contemplated hereby. Each Party further agrees that service of any process, summons,
notice or document by certified or registered mail to such Party’s address set forth in Article 13.1 or such other
address or to the attention of such other person as the recipient Party has specified by prior written notice to the sending Party
shall be effective service of process in any action, suit or proceeding in New York with respect to any matters to which it has
submitted to jurisdiction as set forth above in the immediately preceding sentence. Each Party irrevocably and unconditionally
waives any objection to the laying of venue of any action, suit or proceeding arising out of this Agreement or the transactions
contemplated hereby in the federal or the state courts in New York, NY and hereby irrevocably and unconditionally waives and agrees
not to plead or claim in any such court that any such action, suit or proceeding brought in such court has been brought in an inconvenient
forum.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	24

     

    

 

		13.8	Waiver of Trial by Jury. TO THE FULLEST EXTENT PERMITTED BY LAW, THE PARTIES HEREBY WAIVE
THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY PROCEEDING BASED UPON, ARISING OUT OF, OR RELATED TO THIS AGREEMENT, INCLUDING ANY
DISPUTE ARISING OUT OF OR RELATING TO THE PERFORMANCE THEREOF, OR ANY OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. THE SCOPE
OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE
SUBJECT MATTER OF THIS AGREEMENT, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS AND ALL OTHER COMMON LAW AND STATUTORY
CLAIMS.

 

		13.9	Severability. If any provision in this Agreement is held to be invalid, void or unenforceable,
then the remainder of this Agreement, or the application of such provision to the Parties or to the circumstances other than those
as to which it is held invalid or unenforceable, shall not be affected thereby and shall be enforced to the fullest extent permitted
by law. The Parties agree to renegotiate any such invalid, void or unenforceable provision in good faith in order to provide a
reasonably acceptable alternative consistent with the basic purposes of this Agreement.

 

		13.10	Entire Agreement. This Agreement (including the Schedules attached hereto and the Pharmacovigilance
Agreement and Quality Agreement) constitutes the entire agreement between the Parties with respect to the subject matter hereof,
and all prior or agreements, whether written or oral, are superseded hereby. This Agreement may be amended only in writing executed
by the Parties.

 

		13.11	Sub-contracting. ELITE shall not sub-contract any of the work to be performed under this
Agreement without the prior written consent of GLENMARK. No such sub-contracting shall relieve ELITE of any of its obligations
hereunder.

 

		13.12	Counterparts. This Agreement may be executed in any number of counterparts, each of which
when so executed shall be deemed to be an original and all of which when taken together shall constitute this Agreement.

 

		13.13	Headings. The captions and headings contained herein are for convenience of the Parties
and in no way define, limit or describe the scope of this Agreement.

 

		13.14	Language. The language of this Agreement and all proceedings taken in relation thereto shall
be English.

 

		13.15	Currency. Unless otherwise specifically provided, all references to money amounts are expressed
in terms of United States Dollars (USD) and all payments made pursuant to this Agreement shall be made in that currency.

 

		13.16	Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or pursuant
to any Section of this Agreement are and shall otherwise be deemed to be for purposes of Section 365(n) of Title 11, of the United
States Code (the “Bankruptcy Code”) licenses of rights to "intellectual property" as defined in Section
101(35A) of the Bankruptcy Code. The Parties shall retain and may fully exercise all of their respective rights and elections under
the Bankruptcy Code. Upon the bankruptcy of any Party, the non-bankrupt Party shall use its best efforts to transfer its Product
responsibilities to a third party, unless the bankrupt Party elects to continue, and continues, to perform all of its obligations
under this Agreement.

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	25

     

    

 

		13.17	Construction of Agreement. The terms and provisions of this Agreement represent the results
of negotiations between the Parties and their representatives, each of which has been represented by counsel of its own choosing,
and neither of which has acted under duress or compulsion, whether legal, economic or otherwise. Accordingly, the terms and provisions
of this Agreement shall be interpreted and construed in accordance with their usual and customary meanings, and each of the Parties
hereto hereby waives the application in connection with the interpretation and construction of this Agreement of any rule of law
to the effect that ambiguous or conflicting terms or provisions contained in this Agreement shall be interpreted or construed against
the Party whose attorney prepared the executed draft or any earlier draft of this Agreement.

 

[SIGNATURE PAGE FOLLOWS]

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	26

     

    

 

IN WITNESS WHEREOF, the Parties hereto
have executed this Agreement as of the date first written above.

 

	ELITE PHARMACEUTICALS, INC.	 	GLENMARK PHARMACEUTICALS INC., USA
	 	 	 	 	 
	By:	\\s\Nasrat Hakim	 	By:	\\s\Robert Matsuk
	 	 	 	 	 
	Name:	 	 	Name:	 
	 	 	 	 	 
	Title:	 	 	Title:	 

 

	ELITE LABORATORIES, INC.	 
	 	 	 
	By: 	\\s\Nasrat Hakim	 
	 	 	 
	Name:	 	 
	 	 	 
	Title:	 	 

 

		Schedule A:	Products

 

		Schedule B:	Product Specifications

 

		Schedule C	Quarterly Report for Calculation of Gross Profit

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	27

     

    

 

SCHEDULE A

 

Products and Prices

 

Product List

 

	Generic Name	ANDA #	Reference Listed

Drug	Market

exclusivity grant

from ELITE
	Phendimetrazine 35 mg tablets	40762	Bontil® (Phendimetrazine Tartrate) Tablets, mfg by Valeant Pharm.	Semi-exclusive
	{***} tablets	TBD	{***}	Exclusive

 

Transfer Prices ($/bottle)

 

	Name	Full Batch

Qty.	Bottle Size	Cost per bottle
	Phendimetrazine 35 mg tablet	800,000 tablets	100 count	${***}
	Phendimetrazine 35 mg tablet	800,000 tablets	1000 count	${***}
	{***}	1,440,000	100 count	${***}
	{***}	720,000	100 count	${***}

 

Pricing includes all Product manufacturing
and packaging costs, quality assurance, batch quality control testing and stability testing, and is subject pricing adjustments
in Section 4.1(d).

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	28

     

    

 

Schedule
B

 

Product
Specifications 

Elite Pharmaceuticals Inc.

FINISHED PRODUCT ANALYSIS

 

	{***}	{***}
	Manufacturer:

Elite Laboratories, Inc	{***}	{***}	{***}
	QC#:	{***}	{***}

 

	Test / Method	Specification	Results	Notebook Reference
	{***}	{***}	 	 
	{***}	{***}	 	 
	{***}	{***}	 	 
	{***}	{***}	 	 
	{***}	{***}	 	 
	{***}	{***}	 	 
	{***}	{***}	{***}
	{***}	{***}	{***}

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	29

     

    

 

Schedule
B

 

Product Specifications

Elite Pharmaceuticals Inc.

FINISHED PRODUCT ANALYSIS

 

	{***}	{***}
	Manufacturer:

Elite Laboratories, Inc	{***}	{***}	{***}
	QC#:	{***}	{***}

 

	Test / Method	Specification	Results	Notebook Reference
	{***}	{***}	 	 
	{***}	{***}	 	 
	{***}	{***}	 	 
	{***}	{***}	 	 
	{***}	{***}	 	 
	{***}	{***}	 	 
	{***}	{***}	{***}
	{***}	{***}	{***}

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	30

     

    

 

Schedule
B

 

Product
Specifications 

Elite
Pharmaceuticals Inc.

FINISHED PRODUCT
ANALYSIS

 

	Phendimetrazine
    Tartrate Tablets USP 35 mg	{***}
	Manufacturer:

    Elite Laboratories, Inc	Department:

    Analytics and QC	Version
    0	{***}
	QC#:	Batch#:	{***}

 

	Test
/ Method	Specification	Results	Notebook Reference
	{***}	{***}	 	 
	{***}	{***}	 	 
	{***}	{***}	 	 
	{***}	{***}	 	 
	{***}	{***}	 	 
	{***}	{***}	 	 
	{***}	{***}	 	 
	{***}	{***}	 	 
	{***}	{***}	 	 
	{***}	{***}	 	 
	{***}	{***}	{***}	{***}

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	31

     

    

 

Schedule
C

 

Quarterly Report
for Calculation of Gross Profit

 

Product Name:________________________________________________________

 

	Quantity sold by SKU	XXXX units
	Gross Sales	$
	Deductions:	 
	Chargebacks	 
	Rebates	 
	ADministrative Fees	 
	Billbacks	 
	Returns	 
	Shelf Stock Adjustments	 
	Other deductions	 
	Cash Discounts	 
	Medicaid	 
	NET SALES	$
	Transfer Price	 
	Selling and DIstribution Expenses	 
	Shipping COsts	 
	Gross Profit	 
	Material Write offs	 
	NET PROFIT	 
	Profit share Payment to ELITe  at  {***}%	 

 

    	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
	 
	32EX-4.5

 Exhibit 4.5 
  

BROADCOM INC. 
  

 
 INDENTURE

 Dated as of                     ,
20     
  
  

WILMINGTON TRUST, NATIONAL ASSOCIATION 

Trustee 

 TABLE OF CONTENTS 

 

									
	 	 	 	  	 	  	Page	 
	 ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE
	  	 	1	 
		 	Section 1.1.	  	Definitions	  	 	1	 
		 	Section 1.2.	  	Other Definitions	  	 	4	 
		 	Section 1.3.	  	Incorporation by Reference of Trust Indenture Act.	  	 	5	 
		 	Section 1.4.	  	Rules of Construction	  	 	5	 
		
	ARTICLE II. THE SECURITIES	  	 	5	 
		 	Section 2.1.	  	Issuable in Series	  	 	5	 
		 	Section 2.2.	  	Establishment of Terms of Series of Securities	  	 	6	 
		 	Section 2.3.	  	Execution and Authentication	  	 	8	 
		 	Section 2.4.	  	Registrar and Paying Agent	  	 	9	 
		 	Section 2.5.	  	Paying Agent to Hold Money in Trust	  	 	10	 
		 	Section 2.6.	  	Securityholder Lists	  	 	10	 
		 	Section 2.7.	  	Transfer and Exchange	  	 	10	 
		 	Section 2.8.	  	Mutilated, Destroyed, Lost and Stolen Securities	  	 	11	 
		 	Section 2.9.	  	Outstanding Securities	  	 	12	 
		 	Section 2.10.	  	Treasury Securities	  	 	12	 
		 	Section 2.11.	  	Temporary Securities	  	 	12	 
		 	Section 2.12.	  	Cancellation	  	 	13	 
		 	Section 2.13.	  	Defaulted Interest	  	 	13	 
		 	Section 2.14.	  	Global Securities	  	 	13	 
		 	Section 2.15.	  	CUSIP Numbers	  	 	15	 
		 	Section 2.16.	  	Trustee Not Responsible for Securities Laws	  	 	15	 
		
	ARTICLE III. REDEMPTION	  	 	15	 
		 	Section 3.1.	  	Notice to Trustee	  	 	15	 
		 	Section 3.2.	  	Selection of Securities to be Redeemed	  	 	15	 
		 	Section 3.3.	  	Notice of Redemption	  	 	16	 
		 	Section 3.4.	  	Effect of Notice of Redemption	  	 	17	 
		 	Section 3.5.	  	Deposit of Redemption Price	  	 	17	 
		 	Section 3.6.	  	Securities Redeemed in Part	  	 	17	 
		
	ARTICLE IV. COVENANTS	  	 	17	 
		 	Section 4.1.	  	Payment of Principal and Interest	  	 	17	 
		 	Section 4.2.	  	SEC Reports	  	 	17	 
		 	Section 4.3.	  	Compliance Certificate	  	 	18	 
		 	Section 4.4.	  	Stay, Extension and Usury Laws	  	 	18	 
		
	ARTICLE V. SUCCESSORS	  	 	18	 
		 	Section 5.1.	  	When Company May Merge, Etc.	  	 	18	 
		 	Section 5.2.	  	Successor Corporation Substituted	  	 	19	 

  
 i 

									
	 	 	 	  	 	  	Page	 
	ARTICLE VI. DEFAULTS AND REMEDIES	  	 	19	 
		 	Section 6.1.	  	Events of Default	  	 	19	 
		 	Section 6.2.	  	Acceleration of Maturity; Rescission and Annulment	  	 	20	 
		 	Section 6.3.	  	Collection of Indebtedness and Suits for Enforcement by Trustee	  	 	21	 
		 	Section 6.4.	  	Trustee May File Proofs of Claim	  	 	22	 
		 	Section 6.5.	  	Trustee May Enforce Claims Without Possession of Securities	  	 	22	 
		 	Section 6.6.	  	Application of Money Collected	  	 	23	 
		 	Section 6.7.	  	Limitation on Suits	  	 	23	 
		 	Section 6.8.	  	Unconditional Right of Holders to Receive Principal and Interest	  	 	24	 
		 	Section 6.9.	  	Restoration of Rights and Remedies	  	 	24	 
		 	Section 6.10.	  	Rights and Remedies Cumulative	  	 	24	 
		 	Section 6.11.	  	Delay or Omission Not Waiver	  	 	24	 
		 	Section 6.12.	  	Control by Holders	  	 	24	 
		 	Section 6.13.	  	Waiver of Past Defaults	  	 	25	 
		 	Section 6.14.	  	Undertaking for Costs	  	 	25	 
		
	ARTICLE VII. TRUSTEE	  	 	26	 
		 	Section 7.1.	  	Duties of Trustee	  	 	26	 
		 	Section 7.2.	  	Rights of Trustee	  	 	27	 
		 	Section 7.3.	  	Individual Rights of Trustee	  	 	28	 
		 	Section 7.4.	  	Trustee’s Disclaimer	  	 	29	 
		 	Section 7.5.	  	Notice of Defaults	  	 	29	 
		 	Section 7.6.	  	Reports by Trustee to Holders	  	 	29	 
		 	Section 7.7.	  	Compensation and Indemnity	  	 	29	 
		 	Section 7.8.	  	Replacement of Trustee	  	 	30	 
		 	Section 7.9.	  	Successor Trustee by Merger, Etc.	  	 	31	 
		 	Section 7.10.	  	Eligibility; Disqualification	  	 	31	 
		 	Section 7.11.	  	Preferential Collection of Claims Against Company	  	 	31	 
		
	ARTICLE VIII. SATISFACTION AND DISCHARGE; DEFEASANCE	  	 	31	 
		 	Section 8.1.	  	Satisfaction and Discharge of Indenture	  	 	31	 
		 	Section 8.2.	  	Application of Trust Funds; Indemnification	  	 	32	 
		 	Section 8.3.	  	Legal Defeasance of Securities of any Series	  	 	33	 
		 	Section 8.4.	  	Covenant Defeasance	  	 	34	 
		 	Section 8.5.	  	Repayment to Company	  	 	36	 
		 	Section 8.6.	  	Reinstatement	  	 	36	 
		
	ARTICLE IX. AMENDMENTS AND WAIVERS	  	 	36	 
		 	Section 9.1.	  	Without Consent of Holders	  	 	36	 
		 	Section 9.2.	  	With Consent of Holders	  	 	37	 
		 	Section 9.3.	  	Limitations	  	 	38	 
		 	Section 9.4.	  	Compliance with Trust Indenture Act.	  	 	38	 
		 	Section 9.5.	  	Revocation and Effect of Consents	  	 	38	 
		 	Section 9.6.	  	Notation on or Exchange of Securities	  	 	39	 
		 	Section 9.7.	  	Trustee Protected	  	 	39	 

  
 ii 

									
	 	 	 	  	 	  	Page	 
	ARTICLE X. MISCELLANEOUS	  	 	39	 
		 	Section 10.1.	  	Trust Indenture Act Controls	  	 	39	 
		 	Section 10.2.	  	Notices	  	 	39	 
		 	Section 10.3.	  	Communication by Holders with Other Holders	  	 	41	 
		 	Section 10.4.	  	Certificate and Opinion as to Conditions Precedent	  	 	41	 
		 	Section 10.5.	  	Statements Required in Certificate or Opinion	  	 	41	 
		 	Section 10.6.	  	Rules by Trustee and Agents	  	 	42	 
		 	Section 10.7.	  	Legal Holidays	  	 	42	 
		 	Section 10.8.	  	No Recourse Against Others	  	 	42	 
		 	Section 10.9.	  	Counterparts	  	 	42	 
		 	Section 10.10.	  	Governing Law; Waiver of Jury Trial; Consent to Jurisdiction	  	 	42	 
		 	Section 10.11.	  	No Adverse Interpretation of Other Agreements	  	 	43	 
		 	Section 10.12.	  	Successors	  	 	43	 
		 	Section 10.13.	  	Severability	  	 	43	 
		 	Section 10.14.	  	Table of Contents, Headings, Etc.	  	 	43	 
		 	Section 10.15.	  	Securities in a Foreign Currency	  	 	43	 
		 	Section 10.16.	  	Judgment Currency	  	 	44	 
		 	Section 10.17.	  	Force Majeure	  	 	44	 
		 	Section 10.18.	  	U.S.A. Patriot Act.	  	 	45	 
		
	ARTICLE XI. SINKING FUNDS	  	 	45	 
		 	Section 11.1.	  	Applicability of Article	  	 	45	 
		 	Section 11.2.	  	Satisfaction of Sinking Fund Payments with Securities	  	 	45	 
		 	Section 11.3.	  	Redemption of Securities for Sinking Fund	  	 	46	 

  
 iii 

 BROADCOM INC. 

Reconciliation and tie between Trust Indenture Act of 1939 and 

Indenture, dated as of                     ,
20     
  

					
	 § 310(a)(1)
	 		  	7.10
	 (a)(2)
	 		  	7.10
	 (a)(3)
	 		  	Not Applicable
	 (a)(4)
	 		  	Not Applicable
	 (a)(5)
	 		  	7.10
	 (b)
	 		  	7.10
	 § 311(a)
	 		  	7.11
	 (b)
	 		  	7.11
	 (c)
	 		  	Not Applicable
	 § 312(a)
	 		  	2.6
	 (b)
	 		  	10.3
	 (c)
	 		  	10.3
	 § 313(a)
	 		  	7.6
	 (b)(1)
	 		  	7.6
	 (b)(2)
	 		  	7.6
	 (c)(1)
	 		  	7.6
	 (d)
	 		  	7.6
	 § 314(a)
	 		  	4.2, 10.5
	 (b)
	 		  	Not Applicable
	 (c)(1)
	 		  	10.4
	 (c)(2)
	 		  	10.4
	 (c)(3)
	 		  	Not Applicable
	 (d)
	 		  	Not Applicable
	 (e)
	 		  	10.5
	 (f)
	 		  	Not Applicable
	 § 315(a)
	 		  	7.1
	 (b)
	 		  	7.5
	 (c)
	 		  	7.1
	 (d)
	 		  	7.1
	 (e)
	 		  	6.14
	 § 316(a)
	 		  	2.10
	 (a)(1)(A)
	 		  	6.12
	 (a)(1)(B)
	 		  	6.13
	 (b)
	 		  	6.8
	 § 317(a)(1)
	 		  	6.3
	 (a)(2)
	 		  	6.4
	 (b)
	 		  	2.5
	 § 318(a)
	 		  	10.1

  
 Note: This
reconciliation and tie shall not, for any purpose, be deemed to be part of the Indenture. 
  

  
 iv 

 Indenture dated as of
                    , 20     between BROADCOM INC., a company incorporated under the laws of Delaware
(“Company”), and WILMINGTON TRUST, NATIONAL ASSOCIATION, as trustee (“Trustee”). 
 Each party agrees as
follows for the benefit of the other party and for the equal and ratable benefit of the Holders of the Securities issued under this Indenture. 

ARTICLE I. 

DEFINITIONS AND INCORPORATION BY REFERENCE 

Section 1.1. Definitions. 

“Additional Amounts” means any additional amounts which are required hereby or by any Security, under circumstances specified
herein or therein, to be paid by the Company in respect of certain taxes imposed on Holders specified herein or therein and which are owing to such Holders. 

“Affiliate” of any specified person means any other person directly or indirectly controlling or controlled by or under
common control with such specified person. For the purposes of this definition, “control” (including, with correlative meanings, the terms “controlled by” and “under common control with”), as used with respect to
any person, shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such person, whether through the ownership of voting securities or by agreement or otherwise. 

“Agent” means any Registrar, Paying Agent or Notice Agent. 

“Board of Directors” means the board of directors of the Company or any duly authorized committee thereof. 

“Board Resolution” means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company to have
been adopted by the Board of Directors or pursuant to authorization by the Board of Directors and to be in full force and effect on the date of the certificate and delivered to the Trustee. 

“Business Day” means any day except a Saturday, Sunday or a legal holiday in The City of New York, New York (or in connection
with any payment, the place of payment) on which banking institutions are authorized or required by law, regulation or executive order to close. 

“Capital Stock” means any and all shares, interests, participations, rights or other equivalents (however designated) of
corporate stock. 
 “Company” means the party named as such above until a successor replaces it and thereafter means the
successor. 
 “Company Order” means a written order signed in the name of the Company by an Officer. 

 “Corporate Trust Office” means the office of the Trustee at which at any
particular time its corporate trust business related to this Indenture shall be principally administered. 
 “Default”
means any event which is, or after notice or passage of time or both would be, an Event of Default. 
 “Depositary” means,
with respect to the Securities of any Series issuable or issued in whole or in part in the form of one or more Global Securities, the person designated as Depositary for such Series by the Company, which Depositary shall be a clearing agency
registered under the Exchange Act; and if at any time there is more than one such person, “Depositary” as used with respect to the Securities of any Series shall mean the Depositary with respect to the Securities of such Series. 

“Discount Security” means any Security that provides for an amount less than the stated principal amount thereof to be due
and payable upon declaration of acceleration of the maturity thereof pursuant to Section 6.2. 
 “Dollars” and
“$” means the currency of The United States of America. 
 “Exchange Act” means the Securities Exchange
Act of 1934, as amended. 
 “Foreign Currency” means any currency or currency unit issued by a government other than the
government of The United States of America. 
 “Foreign Government Obligations” means, with respect to Securities of any
Series that are denominated in a Foreign Currency, direct obligations of, or obligations guaranteed by, the government that issued or caused to be issued such currency for the payment of which obligations its full faith and credit is pledged and
which are not callable or redeemable at the option of the issuer thereof. 
 “GAAP” means accounting principles generally
accepted in the United States of America set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting
Standards Board or in such other statements by such other entity as have been approved by a significant segment of the accounting profession, which are in effect as of the date of determination. 

“Global Security” or “Global Securities” means a Security or Securities, as the case may be, in the form
established pursuant to Section 2.2 evidencing all or part of a Series of Securities, issued to the Depositary for such Series or its nominee, and registered in the name of such Depositary or nominee. 

“Holder” or “Securityholder” means a person in whose name a Security is registered. 

  
 2 

 “Indenture” means this Indenture as amended or supplemented from time to time
and shall include the form and terms of particular Series of Securities established as contemplated hereunder. 

“interest” with respect to any Discount Security which by its terms bears interest only after Maturity, means interest
payable after Maturity. 
 “Maturity,” when used with respect to any Security, means the date on which the principal of
such Security becomes due and payable as therein or herein provided, whether at the Stated Maturity or by declaration of acceleration, call for redemption or otherwise. 

“Officer” means the Chief Executive Officer, President, the Chief Financial Officer, the Treasurer or any Assistant
Treasurer, the Secretary or any Assistant Secretary, and any Vice President of the Company, whether or not designated by a number or numbers or a word or words added after the title “Vice President”. 

“Officer’s Certificate” means a certificate signed by any Officer. 

“Opinion of Counsel” means a written opinion of legal counsel who is acceptable to the Trustee. The counsel may be an
employee of or counsel to the Company. The opinion may contain customary limitations, conditions and exceptions. 

“person” means any individual, corporation, partnership, joint venture, association, limited liability company, joint-stock
company, trust, unincorporated organization or government or any agency or political subdivision thereof. 
 “principal” of
a Security means the principal of the Security plus, when appropriate, the premium, if any, on, and any Additional Amounts in respect of, the Security. 

“Responsible Officer” means any officer of the Trustee in its Corporate Trust Office and also means, with respect to a
particular corporate trust matter, any other officer to whom any corporate trust matter is referred because of his or her knowledge of and familiarity with a particular subject, and, in each case, who shall have direct responsibility for the
administration of this Indenture. 
 “SEC” means the Securities and Exchange Commission. 

“Securities” means the debentures, notes or other debt instruments of the Company of any Series authenticated and delivered
under this Indenture. 
 “Series” or “Series of Securities” means each series of debentures, notes or
other debt instruments of the Company created pursuant to Sections 2.1 and 2.2 hereof. 
 “Stated Maturity” when used with
respect to any Security, means the date specified in such Security as the fixed date on which the principal of such Security or interest is due and payable. 

  
 3 

 “Subsidiary” of any specified person means any corporation, association or other
business entity of which more than 50% of the total voting power of shares of Capital Stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or
controlled, directly or indirectly, by such person or one or more of the other Subsidiaries of that person or a combination thereof. 

“TIA” means the Trust Indenture Act of 1939 (15 U.S. Code §§ 77aaa-77bbbb) as in effect on the date of this
Indenture; provided, however, that in the event the Trust Indenture Act of 1939 is amended after such date, “TIA” means, to the extent required by any such amendment, the Trust Indenture Act as so amended. 

“Trustee” means the person named as the “Trustee” in the first paragraph of this instrument until a successor
Trustee shall have become such pursuant to the applicable provisions of this Indenture, and thereafter “Trustee” shall mean or include each person who is then a Trustee hereunder, and if at any time there is more than one such person,
“Trustee” as used with respect to the Securities of any Series shall mean the Trustee with respect to Securities of that Series, which shall be appointed pursuant to a supplemental indenture. 

“U.S. Government Obligations” means securities which are direct obligations of, or guaranteed by, The United States of
America for the payment of which its full faith and credit is pledged and which are not callable or redeemable at the option of the issuer thereof, and shall also include a depositary receipt issued by a bank or trust company as custodian with
respect to any such U.S. Government Obligation or a specific payment of interest on or principal of any such U.S. Government Obligation held by such custodian for the account of the holder of a depository receipt, provided that (except as
required by law) such custodian is not authorized to make any deduction from the amount payable to the holder of such depositary receipt from any amount received by the custodian in respect of the U.S. Government Obligation evidenced by such
depositary receipt. 
 Section 1.2. Other Definitions. 

 

					
	 TERM
	  	DEFINED IN
SECTION	 
	 “Bankruptcy Law”
	  	 	6.1	 
	 “Custodian”
	  	 	6.1	 
	 “Event of Default”
	  	 	6.1	 
	 “Judgment Currency”
	  	 	10.16	 
	 “Legal Holiday”
	  	 	10.7	 
	 “mandatory sinking fund payment”
	  	 	11.1	 
	 “New York Banking Day”
	  	 	10.16	 
	 “Notice Agent”
	  	 	2.4	 
	 “optional sinking fund payment”
	  	 	11.1	 
	 “Paying Agent”
	  	 	2.4	 
	 “Registrar”
	  	 	2.4	 
	 “Required Currency”
	  	 	10.16	 
	 “Specified Courts”
	  	 	10.10	 
	 “successor person”
	  	 	5.1	 

  
 4 

 Section 1.3. Incorporation by Reference of Trust
Indenture Act. 
 Whenever this Indenture refers to a provision of the TIA, the provision is incorporated by reference in and made a
part of this Indenture. The following TIA terms used in this Indenture have the following meanings: 
 “Commission” means
the SEC. 
 “indenture securities” means the Securities. 

“indenture security holder” means a Securityholder. 

“indenture to be qualified” means this Indenture. 

“indenture trustee” or “institutional trustee” means the Trustee. 

“obligor” on the indenture securities means the Company and any successor obligor upon the Securities. 

All other terms used in this Indenture that are defined by the TIA, defined by TIA reference to another statute or defined by SEC rule under
the TIA and not otherwise defined herein are used herein as so defined. 
 Section 1.4. Rules of
Construction. 
 Unless the context otherwise requires: 

(a) a term has the meaning assigned to it; 

(b) an accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP; 

(c) “or” is not exclusive; 

(d) words in the singular include the plural, and in the plural include the singular; and 

(e) provisions apply to successive events and transactions. 

ARTICLE II. 

THE SECURITIES 

Section 2.1. Issuable in Series. 

The aggregate principal amount of Securities that may be authenticated and delivered under this Indenture is unlimited. The Securities may be
issued in one or more Series. 

  
 5 

 
All Securities of a Series shall be identical except as may be set forth or determined in the manner provided in a Board Resolution, a supplemental indenture or an Officer’s Certificate
detailing the adoption of the terms thereof pursuant to authority granted under a Board Resolution. In the case of Securities of a Series to be issued from time to time, the Board Resolution, Officer’s Certificate or supplemental indenture
detailing the adoption of the terms thereof pursuant to authority granted under a Board Resolution may provide for the method by which specified terms (such as interest rate, maturity date, record date or date from which interest shall accrue) are
to be determined. Securities may differ between Series in respect of any matters, provided that all Series of Securities shall be equally and ratably entitled to the benefits of the Indenture. 

Section 2.2. Establishment of Terms of Series of Securities. 

At or prior to the issuance of any Securities within a Series, the following shall be established (as to the Series generally, in the case of
Subsection 2.2.1 and either as to such Securities within the Series or as to the Series generally in the case of Subsections 2.2.2 through 2.2.23) by or pursuant to a Board Resolution, and set forth or determined in the manner provided in a Board
Resolution, supplemental indenture hereto or Officer’s Certificate: 
 2.2.1. the title (which shall distinguish the Securities of
that particular Series from the Securities of any other Series) and ranking (including the terms of any subordination provisions) of the Series; 

2.2.2. the price or prices (expressed as a percentage of the principal amount thereof) at which the Securities of the Series will be
issued; 
 2.2.3. any limit upon the aggregate principal amount of the Securities of the Series which may be authenticated and
delivered under this Indenture (except for Securities authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities of the Series pursuant to Section 2.7, 2.8, 2.11, 3.6 or 9.6); 

2.2.4. the date or dates on which the principal of the Securities of the Series is payable; 

2.2.5. the rate or rates (which may be fixed or variable) per annum or, if applicable, the method used to determine such rate or rates
(including, but not limited to, any commodity, commodity index, stock exchange index or financial index) at which the Securities of the Series shall bear interest, if any, the date or dates from which such interest, if any, shall accrue, the date or
dates on which such interest, if any, shall commence and be payable and any regular record date for the interest payable on any interest payment date; 

2.2.6. the place or places where the principal of and interest, if any, on the Securities of the Series shall be payable, where the
Securities of such Series may be surrendered for registration of transfer or exchange and where notices and demands to or upon the Company in respect of the Securities of such Series and this Indenture may be delivered, and the method of such
payment, if by wire transfer, mail or other means; 

  
 6 

 2.2.7. if applicable, the period or periods within which, the price or prices at which and
the terms and conditions upon which the Securities of the Series may be redeemed, in whole or in part, at the option of the Company; 

2.2.8. the obligation, if any, of the Company to redeem or purchase the Securities of the Series pursuant to any sinking fund or
analogous provisions or at the option of a Holder thereof and the period or periods within which, the price or prices at which and the terms and conditions upon which Securities of the Series shall be redeemed or purchased, in whole or in part,
pursuant to such obligation; 
 2.2.9. the dates, if any, on which and the price or prices at which the Securities of the Series will
be repurchased by the Company at the option of the Holders thereof and other detailed terms and provisions of such repurchase obligations; 

2.2.10. if other than denominations of $1,000 and any integral multiple thereof, the denominations in which the Securities of the Series
shall be issuable; 
 2.2.11. the forms of the Securities of the Series and whether the Securities will be issuable as Global
Securities; 
 2.2.12. if other than the principal amount thereof, the portion of the principal amount of the Securities of the Series
that shall be payable upon declaration of acceleration of the maturity thereof pursuant to Section 6.2; 
 2.2.13. the currency of
denomination of the Securities of the Series, which may be Dollars or any Foreign Currency, and if such currency of denomination is a composite currency, the agency or organization, if any, responsible for overseeing such composite currency; 

2.2.14. the designation of the currency, currencies or currency units in which payment of the principal of and interest, if any, on the
Securities of the Series will be made; 
 2.2.15. if payments of principal of or interest, if any, on the Securities of the Series are
to be made in one or more currencies or currency units other than that or those in which such Securities are denominated, the manner in which the exchange rate with respect to such payments will be determined; 

2.2.16. the manner in which the amounts of payment of principal of or interest, if any, on the Securities of the Series will be
determined, if such amounts may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index; 

2.2.17. the provisions, if any, relating to any security provided for the Securities of the Series; 

2.2.18. any addition to, deletion of or change in the Events of Default which applies to any Securities of the Series and any change in
the right of the Trustee or the requisite Holders of such Securities to declare the principal amount thereof due and payable pursuant to Section 6.2; 

  
 7 

 2.2.19. any addition to, deletion of or change in the covenants set forth in Articles IV or
V which applies to Securities of the Series; 
 2.2.20. any Depositaries, interest rate calculation agents, exchange rate calculation
agents or other agents with respect to Securities of such Series if other than those appointed herein; 
 2.2.21. the provisions, if
any, relating to conversion or exchange of any Securities of such Series, including if applicable, the conversion or exchange price, the conversion or exchange period, provisions as to whether conversion or exchange will be mandatory, at the option
of the Holders thereof or at the option of the Company, the events requiring an adjustment of the conversion price or exchange price and provisions affecting conversion or exchange if such Series of Securities are redeemed; 

2.2.22. any other terms of the Series (which may supplement, modify or delete any provision of this Indenture insofar as it applies to
such Series), including any terms that may be required under applicable law or regulations or advisable in connection with the marketing of Securities of that Series; and 

2.2.23. whether any of the Company’s direct or indirect Subsidiaries will guarantee the Securities of that Series, including the
terms of subordination, if any, of such guarantees. 
 All Securities of any one Series need not be issued at the same time and may be
issued from time to time, consistent with the terms of this Indenture, if so provided by or pursuant to the Board Resolution, supplemental indenture hereto or Officer’s Certificate referred to above. 

Section 2.3. Execution and Authentication. 

An Officer shall sign the Securities for the Company by manual or facsimile signature. 

If an Officer whose signature is on a Security no longer holds that office at the time the Security is authenticated, the Security shall
nevertheless be valid. 
 A Security shall not be valid until authenticated by the manual signature of the Trustee or an authenticating
agent. The signature shall be conclusive evidence that the Security has been authenticated under this Indenture. 
 The Trustee shall at any
time, and from time to time, authenticate Securities for original issue in the principal amount provided in the Board Resolution, supplemental indenture hereto or Officer’s Certificate, upon receipt by the Trustee of a Company Order. Each
Security shall be dated the date of its authentication. 
 The aggregate principal amount of Securities of any Series outstanding at any
time may not exceed any limit upon the maximum principal amount for such Series set forth in the Board Resolution, supplemental indenture hereto or Officer’s Certificate delivered pursuant to Section 2.2, except as provided in
Section 2.8. 

  
 8 

 Prior to the issuance of Securities of any Series, the Trustee shall have received and (subject
to Section 7.2) shall be fully protected in relying on: (a) the Board Resolution, supplemental indenture hereto or Officer’s Certificate establishing the form of the Securities of that Series or of Securities within that Series and
the terms of the Securities of that Series or of Securities within that Series, (b) an Officer’s Certificate complying with Section 10.4, and (c) an Opinion of Counsel complying with Section 10.4. 

The Trustee shall have the right to decline to authenticate and deliver any Securities of such Series: (a) if the Trustee, being advised
by counsel, determines that such action may not be taken lawfully; (b) if the Trustee in good faith by its board of directors or trustees, executive committee or a trust committee of directors and/or vice-presidents or a committee of
Responsible Officers shall determine that such action would expose the Trustee to personal liability to Holders of any then outstanding Series of Securities; or (c) if the Trustee in good faith shall determine that the terms of any such
Securities as set forth in the Board Resolution or Officer’s Certificate would adversely affect it. 
 The Trustee may appoint an
authenticating agent acceptable to the Company to authenticate Securities. An authenticating agent may authenticate Securities whenever the Trustee may do so. Each reference in this Indenture to authentication by the Trustee includes authentication
by such agent. An authenticating agent has the same rights as an Agent to deal with the Company or an Affiliate of the Company. 

Section 2.4. Registrar and Paying Agent. 

The Company shall maintain, with respect to each Series of Securities, at the place or places specified with respect to such Series pursuant
to Section 2.2, an office or agency where Securities of such Series may be presented or surrendered for payment (“Paying Agent”), where Securities of such Series may be surrendered for registration of transfer or exchange
(“Registrar”) and where notices and demands to or upon the Company in respect of the Securities of such Series and this Indenture may be delivered (“Notice Agent”). The Registrar shall keep a register with respect
to each Series of Securities and to their transfer and exchange. The Company will give prompt written notice to the Trustee of the name and address, and any change in the name or address, of each Registrar, Paying Agent or Notice Agent. If at any
time the Company shall fail to maintain any such required Registrar, Paying Agent or Notice Agent or shall fail to furnish the Trustee with the name and address thereof, such presentations, surrenders, notices and demands may be made or served at
the Corporate Trust Office of the Trustee, and the Company hereby appoints the Trustee as its agent to receive all such presentations, surrenders, notices and demands; provided, however, that any appointment of the Trustee as the
Notice Agent shall exclude the appointment of the Trustee or any office of the Trustee as an agent to receive the service of legal process on the Company. 

The Company may also from time to time designate one or more co-registrars, additional paying agents
or additional notice agents and may from time to time rescind such designations; provided, however, that no such designation or rescission shall in any manner 

  
 9 

 
relieve the Company of its obligations to maintain a Registrar, Paying Agent and Notice Agent in each place so specified pursuant to Section 2.2 for Securities of any Series for such
purposes. The Company will give prompt written notice to the Trustee of any such designation or rescission and of any change in the name or address of any such co-registrar, additional paying agent or
additional notice agent. The term “Registrar” includes any co-registrar; the term “Paying Agent” includes any additional paying agent; and the term “Notice
Agent” includes any additional notice agent. The Company or any of its Affiliates may serve as Registrar or Paying Agent. 
 The
Company hereby appoints the Trustee the initial Registrar, Paying Agent and Notice Agent for each Series unless another Registrar, Paying Agent or Notice Agent, as the case may be, is appointed prior to the time Securities of that Series are first
issued. 
 Section 2.5. Paying Agent to Hold Money in Trust. 

The Company shall require each Paying Agent other than the Trustee to agree in writing that the Paying Agent will hold in trust, for the
benefit of Securityholders of any Series of Securities, or the Trustee, all money held by the Paying Agent for the payment of principal of or interest on the Series of Securities, and will notify the Trustee in writing of any default by the Company
in making any such payment. While any such default continues, the Trustee may require a Paying Agent to pay all money held by it to the Trustee. The Company at any time may require a Paying Agent to pay all money held by it to the Trustee. Upon
payment over to the Trustee, the Paying Agent (if other than the Company or a Subsidiary of the Company) shall have no further liability for the money. If the Company or a Subsidiary of the Company acts as Paying Agent, it shall segregate and hold
in a separate trust fund for the benefit of Securityholders of any Series of Securities all money held by it as Paying Agent. Upon any bankruptcy, reorganization or similar proceeding with respect to the Company, the Trustee shall serve as Paying
Agent for the Securities. 
 Section 2.6. Securityholder Lists. 

The Trustee shall preserve in as current a form as is reasonably practicable the most recent list available to it of the names and addresses
of Securityholders of each Series of Securities and shall otherwise comply with TIA § 312(a). If the Trustee is not the Registrar, the Company shall furnish to the Trustee at least ten days before each interest payment date and at such other
times as the Trustee may request in writing a list, in such form and as of such date as the Trustee may reasonably require, of the names and addresses of Securityholders of each Series of Securities. 

Section 2.7. Transfer and Exchange. 

Where Securities of a Series are presented to the Registrar or a co-registrar with a request to
register a transfer or to exchange them for an equal principal amount of Securities of the same Series, the Registrar shall register the transfer or make the exchange if its requirements for such transactions are met. To permit registrations of
transfers and exchanges, the Trustee shall authenticate Securities at the Registrar’s request. No service charge shall be made for any registration of transfer or exchange (except as otherwise expressly permitted herein), but the

  
 10 

 
Company may require payment of a sum sufficient to cover any transfer tax or similar governmental charge payable in connection therewith (other than any such transfer tax or similar governmental
charge payable upon exchanges pursuant to Sections 2.11, 3.6 or 9.6). 
 Neither the Company nor the Registrar shall be required (a) to
issue, register the transfer of, or exchange Securities of any Series for the period beginning at the opening of business fifteen days immediately preceding the sending of a notice of redemption of Securities of that Series selected for redemption
and ending at the close of business on the day such notice is sent, or (b) to register the transfer of or exchange Securities of any Series selected, called or being called for redemption as a whole or the portion being redeemed of any such
Securities selected, called or being called for redemption in part. 
 Section 2.8. Mutilated,
Destroyed, Lost and Stolen Securities. 
 If any mutilated Security is surrendered to the Trustee, the Company shall execute and the
Trustee shall authenticate and deliver in exchange therefor a new Security of the same Series and of like tenor and principal amount and bearing a number not contemporaneously outstanding. 

If there shall be delivered to the Company and the Trustee (i) evidence to their satisfaction of the destruction, loss or theft of any
Security and (ii) such security or indemnity bond as may be required by each of them to hold itself and any of its agents harmless, then, in the absence of notice to the Company or the Trustee that such Security has been acquired by a bona fide
purchaser, the Company shall execute and upon receipt of a Company Order the Trustee shall authenticate and make available for delivery, in lieu of any such destroyed, lost or stolen Security, a new Security of the same Series and of like tenor and
principal amount and bearing a number not contemporaneously outstanding. 
 In case any such mutilated, destroyed, lost or stolen Security
has become or is about to become due and payable, the Company in its discretion may, instead of issuing a new Security, pay such Security. 

Upon the issuance of any new Security under this Section, the Company may require the payment of a sum sufficient to cover any tax or other
governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Trustee) connected therewith. 

Every new Security of any Series issued pursuant to this Section in lieu of any destroyed, lost or stolen Security shall constitute an
original additional contractual obligation of the Company, whether or not the destroyed, lost or stolen Security shall be at any time enforceable by anyone, and shall be entitled to all the benefits of this Indenture equally and proportionately with
any and all other Securities of that Series duly issued hereunder. 
 The provisions of this Section are exclusive and shall preclude (to
the extent lawful) all other rights and remedies with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities. 

  
 11 

 Section 2.9. Outstanding Securities. 

The Securities outstanding at any time are all the Securities authenticated by the Trustee except for those canceled by it, those delivered to
it for cancellation, those reductions in the interest on a Global Security effected by the Trustee in accordance with the provisions hereof and those described in this Section as not outstanding. 

If a Security is replaced pursuant to Section 2.8, it ceases to be outstanding until the Trustee receives proof satisfactory to it that
the replaced Security is held by a bona fide purchaser. 
 If the Paying Agent (other than the Company, a Subsidiary of the Company or an
Affiliate of the Company) holds on the Maturity of Securities of a Series money sufficient to pay such Securities payable on that date, then on and after that date such Securities of the Series cease to be outstanding and interest on them ceases to
accrue. 
 The Company may purchase or otherwise acquire the Securities, whether by open market purchases, negotiated transactions or
otherwise. A Security does not cease to be outstanding because the Company or an Affiliate of the Company holds the Security (but see Section 2.10 below). 

In determining whether the Holders of the requisite principal amount of outstanding Securities have given any request, demand, authorization,
direction, notice, consent or waiver hereunder, the principal amount of a Discount Security that shall be deemed to be outstanding for such purposes shall be the amount of the principal thereof that would be due and payable as of the date of such
determination upon a declaration of acceleration of the Maturity thereof pursuant to Section 6.2. 
 Section 2.10. 
Treasury Securities. 
 In determining whether the Holders of the required principal amount of
Securities of a Series have concurred in any request, demand, authorization, direction, notice, consent or waiver, Securities of a Series owned by the Company or any Affiliate of the Company shall be disregarded, except that for the purposes of
determining whether the Trustee shall be protected in relying on any such request, demand, authorization, direction, notice, consent or waiver only Securities of a Series that a Responsible Officer of the Trustee knows are so owned shall be so
disregarded. 
 Section 2.11. Temporary Securities. 

Until definitive Securities are ready for delivery, the Company may prepare and the Trustee shall authenticate temporary Securities upon a
Company Order. Temporary Securities shall be substantially in the form of definitive Securities but may have variations that the Company considers appropriate for temporary Securities. Without unreasonable delay, the Company shall prepare and the
Trustee upon receipt of a Company Order shall authenticate definitive Securities of the same Series and date of maturity in exchange for temporary Securities. Until so exchanged, temporary securities shall have the same rights under this Indenture
as the definitive Securities. 

  
 12 

 Section 2.12. Cancellation. 

The Company at any time may deliver Securities to the Trustee for cancellation. The Registrar and the Paying Agent shall forward to the
Trustee any Securities surrendered to them for registration of transfer, exchange or payment. The Trustee shall cancel all Securities surrendered for transfer, exchange, payment, replacement or cancellation and shall destroy such canceled Securities
(subject to the record retention requirement of the Exchange Act and the Trustee) and deliver a certificate of such cancellation to the Company upon written request of the Company. The Company may not issue new Securities to replace Securities that
it has paid or delivered to the Trustee for cancellation. 
 Section 2.13. Defaulted
Interest. 
 If the Company defaults in a payment of interest on a Series of Securities, it shall pay the defaulted interest, plus, to
the extent permitted by law, any interest payable on the defaulted interest, to the persons who are Securityholders of the Series on a subsequent special record date. The Company shall fix the record date and payment date. At least 10 days before
the special record date, the Company shall send to the Trustee and to each Securityholder of the Series a notice that states the special record date, the payment date and the amount of interest to be paid. The Company may pay defaulted interest in
any other lawful manner. 
 Section 2.14. Global Securities. 

2.14.1. Terms of Securities. A Board Resolution, a supplemental indenture hereto or an Officer’s Certificate shall establish
whether the Securities of a Series shall be issued in whole or in part in the form of one or more Global Securities and the Depositary for such Global Security or Securities. 

2.14.2. Transfer and Exchange. Notwithstanding any provisions to the contrary contained in Section 2.7 of the Indenture and
in addition thereto, any Global Security shall be exchangeable pursuant to Section 2.7 of the Indenture for Securities registered in the names of Holders other than the Depositary for such Security or its nominee only if (i) such
Depositary notifies the Company that it is unwilling or unable to continue as Depositary for such Global Security or if at any time such Depositary ceases to be a clearing agency registered under the Exchange Act, and, in either case, the Company
fails to appoint a successor Depositary registered as a clearing agency under the Exchange Act within 90 days of such event or (ii) the Company executes and delivers to the Trustee an Officer’s Certificate to the effect that such Global
Security shall be so exchangeable. Any Global Security that is exchangeable pursuant to the preceding sentence shall be exchangeable for Securities registered in such names as the Depositary shall direct in writing in an aggregate principal amount
equal to the principal amount of the Global Security with like tenor and terms. 
 Except as provided in this Section 2.14.2, a Global
Security may not be transferred except as a whole by the Depositary with respect to such Global Security to a nominee of such Depositary, by a nominee of such Depositary to such Depositary or another nominee of such Depositary or by the Depositary
or any such nominee to a successor Depositary or a nominee of such a successor Depositary. 

  
 13 

 2.14.3. Legends. Any Global Security issued hereunder shall bear a legend in
substantially the following form: 
 “THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND
IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE DEPOSITARY. THIS SECURITY IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE
INDENTURE, AND MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY, BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR
DEPOSITARY OR A NOMINEE OF SUCH A SUCCESSOR DEPOSITARY.” 
 In addition, so long as the Depository Trust Company (“DTC”) is
the Depositary, each Global Note registered in the name of DTC or its nominee shall bear a legend in substantially the following form: 

“UNLESS THIS GLOBAL NOTE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION
(“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY GLOBAL NOTE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF
DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE
REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.” 
 2.14.4. Acts of Holders. The Depositary, as a
Holder, may appoint agents and otherwise authorize participants to give or take any request, demand, authorization, direction, notice, consent, waiver or other action which a Holder is entitled to give or take under the Indenture. 

2.14.5. Payments. Notwithstanding the other provisions of this Indenture, unless otherwise specified as contemplated by
Section 2.2, payment of the principal of and interest, if any, on any Global Security shall be made to the Holder thereof. 

2.14.6. Consents, Declaration and Directions. The Company, the Trustee and any Agent shall treat a person as the Holder of such
principal amount of outstanding Securities of such Series represented by a Global Security as shall be specified in a written statement of the Depositary or by the applicable procedures of such Depositary with respect to such Global Security, for
purposes of obtaining any consents, declarations, waivers or directions required to be given by the Holders pursuant to this Indenture. 

  
 14 

 Section 2.15. CUSIP Numbers. 

The Company in issuing the Securities may use “CUSIP” numbers (if then generally in use), and, if so, the Trustee shall use
“CUSIP” numbers in notices of redemption as a convenience to Holders; provided that any such notice may state that no representation is made as to the correctness of such numbers either as printed on the Securities or as contained
in any notice of a redemption and that reliance may be placed only on the other elements of identification printed on the Securities, and any such redemption shall not be affected by any defect in or omission of such numbers. 

Section 2.16. Trustee Not Responsible for Securities Laws. 

Notwithstanding anything herein to the contrary, neither the Trustee nor the Registrar shall be responsible for ascertaining whether any
transfer complies with the registration provisions or exemptions from the Securities Act of 1933, as amended, applicable to state securities laws or other applicable laws. 

ARTICLE III. 

REDEMPTION 
 
Section 3.1. Notice to Trustee. 
 The Company may, with respect to any Series of Securities, reserve the right to
redeem and pay the Series of Securities or may covenant to redeem and pay the Series of Securities or any part thereof prior to the Stated Maturity thereof at such time and on such terms as provided for in such Securities. If a Series of Securities
is redeemable and the Company wants or is obligated to redeem prior to the Stated Maturity thereof all or part of the Series of Securities pursuant to the terms of such Securities, it shall notify the Trustee in writing of the redemption date and
the principal amount of Series of Securities to be redeemed. The Company shall give the notice at least 15 days before the redemption date, unless a shorter period is satisfactory to the Trustee. 

Section 3.2. Selection of Securities to be Redeemed. 

Unless otherwise indicated for a particular Series by a Board Resolution, a supplemental indenture hereto or an Officer’s Certificate, if
less than all the Securities of a Series are to be redeemed, the Securities of the Series to be redeemed will be selected as follows: (a) if the Securities are in the form of Global Securities, in accordance with the procedures of the
Depositary, (b) if the Securities are listed on any national securities exchange, in compliance with the requirements of the principal national securities exchange, if any, on which the Securities are listed, or (c) if not otherwise
provided for under clause (a) or (b) in the manner that the Trustee deems fair and appropriate, including by lot or other method, unless otherwise required by law or applicable stock exchange requirements, subject, in the case of Global
Securities, to the applicable rules and procedures of the Depositary. The Securities to be redeemed shall be selected from Securities of the Series outstanding not previously called for redemption. Portions of the principal of Securities of the
Series that have denominations larger than $1,000 may be selected for redemption. Securities of the Series and portions of them it selected for redemption shall be in amounts of $1,000 or whole multiples of $1,000 or, with

  
 15 

 
respect to Securities of any Series issuable in other denominations pursuant to Section 2.2.10, the minimum principal denomination for each Series and the authorized integral multiples
thereof. Provisions of this Indenture that apply to Securities of a Series called for redemption also apply to portions of Securities of that Series called for redemption. 

Section 3.3. Notice of Redemption. 

Unless otherwise indicated for a particular Series by Board Resolution, a supplemental indenture hereto or an Officer’s Certificate, at
least 15 days but not more than 60 days before a redemption date, the Company shall send or cause to be sent by first-class mail or electronically, in accordance with the procedures of the Depositary, a notice of redemption to each Holder whose
Securities are to be redeemed. 
 The notice shall identify the Securities of the Series to be redeemed and shall state: 

(a) the redemption date; 

(b) the redemption price; 

(c) the name and address of the Paying Agent; 

(d) if any Securities are being redeemed in part, the portion of the principal amount of such Securities to be redeemed
and that, after the redemption date and upon surrender of such Security, a new Security or Securities in principal amount equal to the unredeemed portion of the original Security shall be issued in the name of the Holder thereof upon cancellation of
the original Security; 
 (e) that Securities of the Series called for redemption must be surrendered to the Paying
Agent to collect the redemption price; 
 (f) that interest on Securities of the Series called for redemption ceases to
accrue on and after the redemption date unless the Company defaults in the deposit of the redemption price; 
 (g) the
CUSIP number, if any; and 
 (h) any other information as may be required by the terms of the particular Series or the
Securities of a Series being redeemed. 
 At the Company’s request, the Trustee shall give the notice of redemption in the
Company’s name and at its expense, provided, however, that the Company has delivered to the Trustee, at least 10 days (unless a shorter time shall be acceptable to the Trustee) prior to the notice date, an Officer’s Certificate requesting
that the Trustee give such notice and setting forth the information to be stated in such notice. 

  
 16 

 Section 3.4. Effect of Notice of Redemption. 

Once notice of redemption is sent as provided in Section 3.3, Securities of a Series called for redemption become due and payable on the
redemption date and at the redemption price. Except as otherwise provided in the supplemental indenture, Board Resolution or Officer’s Certificate for a Series, a notice of redemption may not be conditional. Upon surrender to the Paying Agent,
such Securities shall be paid at the redemption price plus accrued interest to the redemption date. 

Section 3.5. Deposit of Redemption Price. 

On or before 11:00 a.m., New York City time, on the redemption date, the Company shall deposit with the Paying Agent money sufficient to pay
the redemption price of and accrued interest, if any, on all Securities to be redeemed on that date. 

Section 3.6. Securities Redeemed in Part. 

Upon surrender of a Security that is redeemed in part, the Trustee shall authenticate for the Holder a new Security of the same Series and the
same maturity equal in principal amount to the unredeemed portion of the Security surrendered. 
 ARTICLE IV.

 COVENANTS 
 
Section 4.1. Payment of Principal and Interest. 
 The Company covenants and agrees for the benefit of the Holders of
each Series of Securities that it will duly and punctually pay the principal of and interest, if any, on the Securities of that Series in accordance with the terms of such Securities and this Indenture. On or before 11:00 a.m., New York City time,
on the applicable payment date, the Company shall deposit with the Paying Agent money sufficient to pay the principal of and interest, if any, on the Securities of each Series in accordance with the terms of such Securities and this Indenture. 

Section 4.2. SEC Reports. 

To the extent any Securities of a Series are outstanding, the Company shall deliver to the Trustee within 15 days after it files them with the
SEC copies of the annual reports and of the information, documents, and other reports (or copies of such portions of any of the foregoing as the SEC may by rules and regulations prescribe) which the Company is required to file with the SEC pursuant
to Section 13 or 15(d) of the Exchange Act. The Company also shall comply with the other provisions of TIA § 314(a). Reports, information and documents filed with the SEC via the EDGAR system will be deemed to be delivered to the Trustee
as of the time of such filing via EDGAR for purposes of this Section 4.2. 
 Delivery of reports, information and documents to the
Trustee under this Section 4.2 are for informational purposes only and the Trustee’s receipt of the foregoing shall not constitute constructive or actual notice of any information contained therein or determinable from information
contained therein, including the Company’s compliance with any of their covenants hereunder (as to which the Trustee is entitled to rely exclusively on Officer’s Certificates). 

  
 17 

 Section 4.3. Compliance Certificate. 

To the extent any Securities of a Series are outstanding, the Company shall deliver to the Trustee, within 120 days after the end of each
fiscal year of the Company, an Officer’s Certificate stating that a review of the activities of the Company and its Subsidiaries during the preceding fiscal year has been made under the supervision of the signing Officers with a view to
determining whether the Company has kept, observed, performed and fulfilled its obligations under this Indenture, and further stating, as to each such Officer signing such certificate, that to the best of his/her knowledge the Company has kept,
observed, performed and fulfilled each and every covenant contained in this Indenture and is not in default in the performance or observance of any of the terms, provisions and conditions hereof (or, if a Default or Event of Default shall have
occurred, describing all such Defaults or Events of Default of which the Officer may have knowledge). 

Section 4.4. Stay, Extension and Usury Laws. 

The Company covenants (to the extent that it may lawfully do so) that it will not at any time insist upon, plead, or in any manner whatsoever
claim or take the benefit or advantage of, any stay, extension or usury law wherever enacted, now or at any time hereafter in force, which may affect the covenants or the performance of this Indenture or the Securities; and the Company (to the
extent it may lawfully do so) hereby expressly waives all benefit or advantage of any such law and covenants that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted to the Trustee, but will
suffer and permit the execution of every such power as though no such law has been enacted. 
 ARTICLE V.

 SUCCESSORS 
 
Section 5.1. When Company May Merge, Etc. 
 The Company shall not consolidate with or merge with or into, or convey,
transfer or lease all or substantially all of its properties and assets to, any person (a “successor person”) unless: 

(a) the Company is the surviving corporation or the successor person (if other than the Company) is a corporation
organized and validly existing under the laws of the Republic of Singapore, any member state of the European Union, the Cayman Islands or any U.S. domestic jurisdiction and expressly assumes the Company’s obligations on the Securities and under
this Indenture; and 
 (b) immediately after giving effect to the transaction, no Default or Event of Default, shall
have occurred and be continuing. 
 The Company shall deliver to the Trustee prior to the consummation of the proposed transaction an
Officer’s Certificate to the foregoing effect and an Opinion of Counsel stating that the proposed transaction and any supplemental indenture comply with this Indenture. 

  
 18 

 Notwithstanding the above, any Subsidiary of the Company may consolidate with, merge into or
transfer all or part of its properties to the Company. Neither an Officer’s Certificate nor an Opinion of Counsel shall be required to be delivered in connection therewith. 

Section 5.2. Successor Corporation Substituted. 

Upon any consolidation or merger, or any sale, lease, conveyance or other disposition of all or substantially all of the assets of the Company
in accordance with Section 5.1, the successor corporation formed by such consolidation or into or with which the Company is merged or to which such sale, lease, conveyance or other disposition is made shall succeed to, and be substituted for,
and may exercise every right and power of, the Company under this Indenture with the same effect as if such successor person has been named as the Company herein; provided, however, that the predecessor Company in the case of a sale,
conveyance or other disposition (other than a lease) shall be released from all obligations and covenants under this Indenture and the Securities. 

ARTICLE VI. 

DEFAULTS AND REMEDIES 
 
Section 6.1. Events of Default. 
 “Event of Default,” wherever used herein with respect to Securities
of any Series, means any one of the following events, unless in the establishing Board Resolution, supplemental indenture or Officer’s Certificate, it is provided that such Series shall not have the benefit of said Event of Default: 

(a) default in the payment of any interest on any Security of that Series when it becomes due and payable, and continuance
of such default for a period of 30 days (unless the entire amount of such payment is deposited by the Company with the Trustee or with a Paying Agent prior to 11:00 a.m., New York City time, on the
30th day of such period); or 
 (b) default in the payment of
principal of any Security of that Series at its Maturity; or 
 (c) default in the performance or breach of any covenant
or warranty of the Company in this Indenture (other than defaults pursuant to paragraphs (a) or (b) above or pursuant to a covenant or warranty that has been included in this Indenture solely for the benefit of Series of Securities other than
that Series), which default continues uncured for a period of 60 days after there has been given, by registered or certified mail, to the Company by the Trustee or to the Company and the Trustee by the Holders of at least 25% in principal amount of
the outstanding Securities of that Series a written notice specifying such default or breach and requiring it to be remedied and stating that such notice is a “Notice of Default” hereunder; or 

(d) the Company pursuant to or within the meaning of any Bankruptcy Law: 

(i) commences a voluntary case, 

  
 19 

 (ii) consents to the entry of an order for relief against it in an
involuntary case, 
 (iii) consents to the appointment of a Custodian of it or for all or substantially all of its
property, 
 (iv) makes a general assignment for the benefit of its creditors, or 

(v) generally is unable to pay its debts as the same become due; or 

(e) a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that: 

(i) is for relief against the Company in an involuntary case, 

(ii) appoints a Custodian of the Company or for all or substantially all of its property, or 

(iii) orders the liquidation of the Company, 

and the order or decree remains unstayed and in effect for 60 days; or 

(f) any other Event of Default provided with respect to Securities of that Series, which is specified in a Board
Resolution, a supplemental indenture hereto or an Officer’s Certificate, in accordance with Section 2.2.18. 
 The term
“Bankruptcy Law” means title 11, U.S. Code or any similar Federal or State law for the relief of debtors. The term “Custodian” means any receiver, trustee, assignee, liquidator or similar official under any
Bankruptcy Law. 
 The Company will provide the Trustee written notice of any Default or Event of Default within 30 days of becoming aware
of the occurrence of such Default or Event of Default, which notice will describe in reasonable detail the status of such Default or Event of Default and what action the Company is taking or proposes to take in respect thereof. 

Section 6.2. Acceleration of Maturity; Rescission and Annulment. 

If an Event of Default with respect to Securities of any Series at the time outstanding occurs and is continuing (other than an Event of
Default referred to in Section 6.1(d) or (e)) then in every such case the Trustee or the Holders of not less than 25% in principal amount of the outstanding Securities of that Series may declare the principal amount (or, if any Securities of
that Series are Discount Securities, such portion of the principal amount as may be specified in the terms of such Securities) of and accrued and unpaid interest, if any, on all of the Securities of that Series to be due and payable immediately, by
a notice in writing to the Company (and to the Trustee if given by Holders), and upon any such declaration such principal amount (or specified amount) and accrued and unpaid interest, if any, shall become immediately due and payable. If an Event of
Default specified in Section 6.1(d) or (e) shall occur, the principal amount (or specified amount) of and accrued and unpaid interest, if any, on all outstanding Securities shall ipso facto become and be immediately due and payable
without any declaration or other act on the part of the Trustee or any Holder. 

  
 20 

 At any time after such a declaration of acceleration with respect to any Series has been made and
before a judgment or decree for payment of the money due has been obtained by the Trustee as hereinafter in this Article provided, the Holders of a majority in principal amount of the outstanding Securities of that Series, by written notice to the
Company and the Trustee, may rescind and annul such declaration and its consequences if all Events of Default with respect to Securities of that Series, other than the non-payment of the principal and
interest, if any, of Securities of that Series which have become due solely by such declaration of acceleration, have been cured or waived as provided in Section 6.13. 

No such rescission shall affect any subsequent Default or impair any right consequent thereon. 

Section 6.3. Collection of Indebtedness and Suits for Enforcement by Trustee. 

The Company covenants that if 

(a) default is made in the payment of any interest on any Security when such interest becomes due and payable and such
default continues for a period of 30 days, or 
 (b) default is made in the payment of principal of any Security at the
Maturity thereof, or 
 (c) default is made in the deposit of any sinking fund payment, if any, when and as due by the
terms of a Security, 
 then, the Company will, upon demand of the Trustee, pay to it, for the benefit of the Holders of such Securities, the whole
amount then due and payable on such Securities for principal and interest and, to the extent that payment of such interest shall be legally enforceable, interest on any overdue principal and any overdue interest at the rate or rates prescribed
therefor in such Securities, and, in addition thereto, such further amount as shall be sufficient to cover the costs and expenses of collection, including the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents
and counsel. 
 If the Company fails to pay such amounts forthwith upon such demand, the Trustee, in its own name and as trustee of an
express trust, may institute a judicial proceeding for the collection of the sums so due and unpaid, may prosecute such proceeding to judgment or final decree and may enforce the same against the Company or any other obligor upon such Securities and
collect the moneys adjudged or deemed to be payable in the manner provided by law out of the property of the Company or any other obligor upon such Securities, wherever situated. 

If an Event of Default with respect to any Securities of any Series occurs and is continuing, the Trustee may in its discretion proceed to
protect and enforce its rights and the rights of the Holders of Securities of such Series by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any such rights, whether for the specific enforcement
of any covenant or agreement in this Indenture or in aid of the exercise of any power granted herein, or to enforce any other proper remedy. 

  
 21 

 Section 6.4. Trustee May File Proofs of Claim.

 In case of the pendency of any receivership, insolvency, liquidation, bankruptcy, reorganization, arrangement, adjustment, composition or
other judicial proceeding relative to the Company or any other obligor upon the Securities or the property of the Company or of such other obligor or their creditors, the Trustee (irrespective of whether the principal of the Securities shall then be
due and payable as therein expressed or by declaration or otherwise and irrespective of whether the Trustee shall have made any demand on the Company for the payment of overdue principal or interest) shall be entitled and empowered, by intervention
in such proceeding or otherwise, 
 (a) to file and prove a claim for the whole amount of principal and interest owing
and unpaid in respect of the Securities and to file such other papers or documents as may be necessary or advisable in order to have the claims of the Trustee (including any claim for the compensation, reasonable expenses, disbursements and advances
of the Trustee, its agents and counsel) and of the Holders allowed in such judicial proceeding, and 
 (b) to collect
and receive any moneys or other property payable or deliverable on any such claims and to distribute the same, 
 and any custodian, receiver, assignee,
trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Holder to make such payments to the Trustee and, in the event that the Trustee shall consent to the making of such payments
directly to the Holders, to pay to the Trustee any amount due it for the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel, and any other amounts due the Trustee under Section 7.7. 

Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Holder any
plan of reorganization, arrangement, adjustment or composition affecting the Securities or the rights of any Holder thereof or to authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding. 

Section 6.5. Trustee May Enforce Claims Without Possession of Securities. 

All rights of action and claims under this Indenture or the Securities may be prosecuted and enforced by the Trustee without the possession of
any of the Securities or the production thereof in any proceeding relating thereto, and any such proceeding instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment shall, after
provision for the payment of the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel, be for the ratable benefit of the Holders of the Securities in respect of which such judgment has been recovered.

  
 22 

 Section 6.6. Application of Money Collected.

 Any money or property collected by the Trustee pursuant to this Article shall be applied in the following order, at the date or dates
fixed by the Trustee and, in case of the distribution of such money or property on account of principal or interest, upon presentation of the Securities and the notation thereon of the payment if only partially paid and upon surrender thereof if
fully paid: 
 First: To the payment of all amounts due the Trustee under Section 7.7; and 

Second: To the payment of the amounts then due and unpaid for principal of and interest on the Securities in respect of which or for the
benefit of which such money has been collected, ratably, without preference or priority of any kind, according to the amounts due and payable on such Securities for principal and interest, respectively; and 

Third: 
To the Company. 
 Section 6.7. Limitation on Suits. 

No Holder of any Security of any Series shall have any right to institute any proceeding, judicial or otherwise, with respect to this
Indenture, or for the appointment of a receiver or trustee, or for any other remedy hereunder, unless 
 (a) such Holder
has previously given written notice to the Trustee of a continuing Event of Default with respect to the Securities of that Series; 

(b) the Holders of not less than 25% in principal amount of the outstanding Securities of that Series shall have made
written request to the Trustee to institute proceedings in respect of such Event of Default in its own name as Trustee hereunder; 

(c) such Holder or Holders have offered to the Trustee indemnity or security satisfactory to the Trustee against the
costs, expenses and liabilities which might be incurred by the Trustee in compliance with such request; 
 (d) the
Trustee for 60 days after its receipt of such notice, request and offer of indemnity has failed to institute any such proceeding; and 

(e) no direction inconsistent with such written request has been given to the Trustee during such 60-day period by the Holders of a majority in principal amount of the outstanding Securities of that Series; 
 it being
understood, intended and expressly covenanted by the Holder of every Security with every other Holder and the Trustee that no one or more of such Holders shall have any right in any manner whatever by virtue of, or by availing of, any provision of
this Indenture to affect, disturb or prejudice the rights of any other of such Holders, or to obtain or to seek to obtain priority or preference over any other of such Holders or to enforce any right under this Indenture, except in the manner herein
provided and for the equal and ratable benefit of all such Holders of the applicable Series. 

  
 23 

 Section 6.8. Unconditional Right of Holders to
Receive Principal and Interest. 
 Notwithstanding any other provision in this Indenture, the Holder of any Security shall have the
right, which is absolute and unconditional, to receive payment of the principal of and interest, if any, on such Security on the Maturity of such Security, including the Stated Maturity expressed in such Security (or, in the case of redemption, on
the redemption date) and to institute suit for the enforcement of any such payment, and such rights shall not be impaired without the consent of such Holder. 

Section 6.9. Restoration of Rights and Remedies. 

If the Trustee or any Holder has instituted any proceeding to enforce any right or remedy under this Indenture and such proceeding has been
discontinued or abandoned for any reason, or has been determined adversely to the Trustee or to such Holder, then and in every such case, subject to any determination in such proceeding, the Company, the Trustee and the Holders shall be restored
severally and respectively to their former positions hereunder and thereafter all rights and remedies of the Trustee and the Holders shall continue as though no such proceeding had been instituted. 

Section 6.10. Rights and Remedies Cumulative. 

Except as otherwise provided with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities in
Section 2.8, no right or remedy herein conferred upon or reserved to the Trustee or to the Holders is intended to be exclusive of any other right or remedy, and every right and remedy shall, to the extent permitted by law, be cumulative and in
addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not, to the extent permitted by law, prevent
the concurrent assertion or employment of any other appropriate right or remedy. 

Section 6.11. Delay or Omission Not Waiver. 

No delay or omission of the Trustee or of any Holder of any Securities to exercise any right or remedy accruing upon any Event of Default
shall impair any such right or remedy or constitute a waiver of any such Event of Default or an acquiescence therein. Every right and remedy given by this Article or by law to the Trustee or to the Holders may be exercised from time to time, and as
often as may be deemed expedient, by the Trustee or by the Holders, as the case may be. 

Section 6.12. Control by Holders. 

The Holders of a majority in principal amount of the outstanding Securities of any Series shall have the right to direct the time, method and
place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee, with respect to the Securities of such Series, provided that 

  
 24 

 (a) such direction shall not be in conflict with any rule of law or with
this Indenture, 
 (b) the Trustee may take any other action deemed proper by the Trustee which is not inconsistent with
such direction, 
 (c) subject to the provisions of Section 7.1, the Trustee shall have the right to decline to
follow any such direction if the Trustee in good faith shall, by a Responsible Officer of the Trustee, determine that the proceeding so directed would involve the Trustee in personal liability, and 

(d) prior to taking any action as directed under this Section 6.12, the Trustee shall be entitled to indemnity
satisfactory to it against the costs, expenses and liabilities which might be incurred by it in compliance with such request or direction. 

Section 6.13. Waiver of Past Defaults. 

The Holders of not less than a majority in principal amount of the outstanding Securities of any Series may on behalf of the Holders of all
the Securities of such Series, by written notice to the Trustee and the Company, waive any past Default hereunder with respect to such Series and its consequences, except a Default in the payment of the principal of or interest on any Security of
such Series (provided, however, that the Holders of a majority in principal amount of the outstanding Securities of any Series may rescind an acceleration and its consequences, including any related payment default that resulted from such
acceleration). Upon any such waiver, such Default shall cease to exist, and any Event of Default arising therefrom shall be deemed to have been cured, for every purpose of this Indenture; but no such waiver shall extend to any subsequent or other
Default or impair any right consequent thereon. 
 Section 6.14. Undertaking for Costs.

 All parties to this Indenture agree, and each Holder of any Security by his acceptance thereof shall be deemed to have agreed, that any
court may in its discretion require, in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken, suffered or omitted by it as Trustee, the filing by any party litigant in such
suit of an undertaking to pay the costs of such suit, and that such court may in its discretion assess reasonable costs, including reasonable attorneys’ fees, against any party litigant in such suit, having due regard to the merits and good
faith of the claims or defenses made by such party litigant; but the provisions of this Section shall not apply to any suit instituted by the Company, to any suit instituted by the Trustee, to any suit instituted by any Holder, or group of Holders,
holding in the aggregate more than 10% in principal amount of the outstanding Securities of any Series, or to any suit instituted by any Holder for the enforcement of the payment of the principal of or interest on any Security on or after the
Maturity of such Security, including the Stated Maturity expressed in such Security (or, in the case of redemption, on the redemption date). 

  
 25 

 ARTICLE VII. 

TRUSTEE 
 
Section 7.1. Duties of Trustee. 
 (a) If an Event of Default has occurred and is continuing, the
Trustee shall exercise the rights and powers vested in it by this Indenture and use the same degree of care and skill in their exercise as a prudent person would exercise or use under the circumstances in the conduct of such person’s own
affairs. 
 (b) Except during the continuance of an Event of Default: 

(i) The Trustee need perform only those duties that are specifically set forth in this Indenture and no others. 

(ii) In the absence of bad faith on its part, the Trustee may conclusively rely, as to the truth of the statements and the
correctness of the opinions expressed therein, upon Officer’s Certificates or Opinions of Counsel furnished to the Trustee and conforming to the requirements of this Indenture; however, in the case of any such Officer’s Certificates
or Opinions of Counsel which by any provisions hereof are specifically required to be furnished to the Trustee, the Trustee shall examine such Officer’s Certificates and Opinions of Counsel to determine whether or not they conform to the form
requirements of this Indenture. 
 (c) The Trustee may not be relieved from liability for its own negligent action, its
own negligent failure to act or its own willful misconduct, except that: 
 (i) This paragraph does not limit the effect
of paragraph (b) of this Section. 
 (ii) The Trustee shall not be liable for any error of judgment made in good
faith by a Responsible Officer, unless it is proved that the Trustee was negligent in ascertaining the pertinent facts. 

(iii) The Trustee shall not be liable with respect to any action taken, suffered or omitted to be taken by it with respect
to Securities of any Series in good faith in accordance with the direction of the Holders of a majority in principal amount of the outstanding Securities of such Series relating to the time, method and place of conducting any proceeding for any
remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee, under this Indenture with respect to the Securities of such Series in accordance with Section 6.12. 

(d) Every provision of this Indenture that in any way relates to the Trustee is subject to this Section and
Section 7.2. 

  
 26 

 (e) The Trustee will be under no obligation to exercise any of its rights or
powers unless it receives indemnity satisfactory to it against the costs, expenses and liabilities which might be incurred by it in exercising such right or power. 

(f) The Trustee shall not be liable for interest on any money received by it except as the Trustee may agree in writing
with the Company. Money held in trust by the Trustee need not be segregated from other funds except to the extent required by law. 

(g) No provision of this Indenture shall require the Trustee to risk its own funds or otherwise incur any financial
liability in the performance of any of its duties, or in the exercise of any of its rights or powers, if adequate indemnity against such risk is not assured to the Trustee in its satisfaction. 

(h) The Paying Agent, the Registrar and any authenticating agent shall be entitled to the protections and immunities as
are set forth in paragraphs (e), (f) and (g) of this Section and in Section 
7.2, each with respect to the Trustee. 
 Section 7.2. Rights of Trustee. 

(a) The Trustee may rely on and shall be protected in acting or refraining from acting upon any document (whether in its
original or facsimile form) believed by it to be genuine and to have been signed or presented by the proper person. The Trustee need not investigate any fact or matter stated in the document. 

(b) Before the Trustee acts or refrains from acting, it may require an Officer’s Certificate or an Opinion of Counsel
or both. The Trustee shall not be liable for any action it takes or omits to take in good faith in reliance on such Officer’s Certificate or Opinion of Counsel. 

(c) The Trustee may act through agents and shall not be responsible for the misconduct or negligence of any agent
appointed with due care. No Depositary shall be deemed an agent of the Trustee and the Trustee shall not be responsible for any act or omission by any Depositary. 

(d) The Trustee shall not be liable for any action it takes or omits to take in good faith which it believes to be
authorized or within its rights or powers, provided that the Trustee’s conduct does not constitute willful misconduct or negligence. 

(e) The Trustee may consult with counsel and the advice of such counsel or any Opinion of Counsel shall be full and
complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder without willful misconduct or negligence, and in reliance thereon. 

(f) The Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the
request or direction of any of the Holders of Securities unless such Holders shall have offered to the Trustee security or indemnity satisfactory to it against the costs, expenses and liabilities which might be incurred by it in compliance with such
request or direction. 

  
 27 

 (g) The Trustee shall not be bound to make any investigation into the facts
or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence of indebtedness or other paper or document, but the Trustee, in its
discretion, may make such further inquiry or investigation into such facts or matters as it may see fit. 
 (h) The
Trustee shall not be deemed to have notice of any Default or Event of Default unless a Responsible Officer of the Trustee has actual knowledge thereof or unless written notice of any event which is in fact such a default is received by the Trustee
at the Corporate Trust Office of the Trustee, and such notice references the Securities generally or the Securities of a particular Series and this Indenture. 

(i) In no event shall the Trustee be liable to any person for special, punitive, indirect, consequential or incidental
loss or damage of any kind whatsoever (including but not limited to lost profits), even if the Trustee has been advised of the likelihood of such loss or damage. 

(j) The permissive right of the Trustee to take the actions permitted by this Indenture shall not be construed as an
obligation or duty to do so. 
 (k) The Trustee is not responsible for monitoring the performance of other persons or
for the failure of others to perform their duties. 
 (l) Any action taken, or omitted to be taken, by the Trustee in
good faith pursuant to this Indenture upon the request or authority or consent of any person who, at the time of making such request or giving such authority or consent, is the holder of any Note shall be conclusive and binding upon future holders
of Notes, and upon Notes executed and delivered in exchange therefor or in place thereof. 
 (m) The Trustee may request
that the Issuer deliver an Officer’s Certificate setting forth the names of individuals and/or titles of officers authorized at such time to take specified actions pursuant to this Indenture, which Officer’s Certificate may be signed by
any Person authorized to sign an Officer’s Certificate, including any Person specified as so authorized in any certificate previously delivered and not superseded. 

(n) The Trustee shall not be required to give any bond or surety in respect of the execution of the trusts and powers
under this Indenture. 
 Section 7.3. Individual Rights of Trustee. 

The Trustee in its individual or any other capacity may become the owner or pledgee of Securities and may otherwise deal with the Company or
an Affiliate of the Company with the same rights it would have if it were not Trustee. Any Agent may do the same with like rights. The Trustee is also subject to Sections 7.10 and 7.11. 

  
 28 

 Section 7.4. Trustee’s Disclaimer. 

The Trustee makes no representation as to the validity or adequacy of this Indenture or the Securities, it shall not be accountable for the
Company’s use of the proceeds from the Securities, and it shall not be responsible for any statement in the Securities other than its authentication. 

Section 7.5. Notice of Defaults. 

If a Default or Event of Default occurs and is continuing with respect to the Securities of any Series and if it is actually known to a
Responsible Officer of the Trustee, the Trustee shall send to each Securityholder of the Securities of that Series notice of a Default or Event of Default within 90 days after it occurs or, if later, after a Responsible Officer of the Trustee has
actual knowledge of such Default or Event of Default. Except in the case of a Default or Event of Default in payment of principal of or interest on any Security of any Series, the Trustee may withhold the notice if and so long as its corporate trust
committee or a committee of its Responsible Officers in good faith determines that withholding the notice is in the interests of Securityholders of that Series. 

Section 7.6. Reports by Trustee to Holders. 

Within 60 days after each             commencing
            , 20    , the Trustee shall transmit by mail to all Securityholders, as their names and addresses appear on the register kept by the Registrar, a brief
report dated as of such anniversary date, in accordance with, and to the extent required under, TIA § 313. 
 A copy of each report at
the time of its mailing to Securityholders of any Series shall be filed with the SEC and each national securities exchange on which the Securities of that Series are listed. The Company shall promptly notify the Trustee in writing when Securities of
any Series are listed on any national securities exchange. 
 Section 7.7. Compensation and
Indemnity. 
 The Company shall pay to the Trustee from time to time compensation for its services as the Company and the Trustee shall
from time to time agree upon in writing. The Trustee’s compensation shall not be limited by any law on compensation of a trustee of an express trust. The Company shall reimburse the Trustee upon request for all reasonable out of pocket expenses
incurred by it. Such expenses shall include the reasonable compensation and expenses of the Trustee’s agents and counsel. 
 The
Company shall indemnify and hold harmless each of the Trustee and any predecessor Trustee (including for the cost of defending itself or this indemnity) against any cost, expense or liability, including taxes (other than taxes based upon, measured
by or determined by the income of the Trustee) incurred by it as Trustee or Agent under this indenture except as set forth in the next paragraph in the performance of its duties under this Indenture as Trustee or Agent. The Trustee shall notify the
Company promptly of any third party claim for which it may seek indemnity. Failure by the Trustee to so notify the Company shall not relieve the Company of its obligations hereunder. The Company shall defend any third party claim and the Trustee

  
 29 

 
shall cooperate in the defense. The Trustee may have one separate counsel plus local counsel, if applicable, and the Company shall pay the reasonable fees and expenses of such counsel. The
Company need not pay for any settlement made without its consent, which consent will not be unreasonably withheld. This indemnification shall apply to officers, directors, employees, shareholders and agents of the Trustee. 

The Company need not reimburse any expense or indemnify against any loss or liability incurred by the Trustee or by any officer, director,
employee, shareholder or agent of the Trustee through willful misconduct or negligence. 
 To secure the Company’s payment obligations
in this Section, the Trustee shall have a lien prior to the Securities of any Series on all money or property held or collected by the Trustee, except that held in trust to pay principal of and interest on particular Securities of that Series. 

When the Trustee incurs expenses or renders services after an Event of Default specified in Section 6.1(d) or (e) occurs, the
expenses and the compensation for the services are intended to constitute expenses of administration under any Bankruptcy Law. 
 The
provisions of this Section shall survive the termination of this Indenture and the resignation or removal of the Trustee. 
 
Section 7.8. Replacement of Trustee. 
 A resignation or removal of the Trustee and appointment of a successor Trustee
shall become effective only upon the successor Trustee’s acceptance of appointment as provided in this Section. 
 The Trustee may
resign with respect to the Securities of one or more Series by so notifying the Company at least 30 days prior to the date of the proposed resignation. The Holders of a majority in principal amount of the Securities of any Series may remove the
Trustee with respect to that Series by so notifying the Trustee and the Company. The Company may remove the Trustee with respect to Securities of one or more Series if: 

(a) the Trustee fails to comply with Section 7.10; 

(b) the Trustee is adjudged a bankrupt or an insolvent or an order for relief is entered with respect to the Trustee under
any Bankruptcy Law; 
 (c) a Custodian or public officer takes charge of the Trustee or its property; or 

(d) the Trustee becomes incapable of acting. 

If the Trustee resigns or is removed or if a vacancy exists in the office of Trustee for any reason, the Company shall promptly appoint a
successor Trustee. Within one year after the successor Trustee takes office, the Holders of a majority in principal amount of the then outstanding Securities may appoint a successor Trustee to replace the successor Trustee appointed by the Company.

  
 30 

 If a successor Trustee with respect to the Securities of any one or more Series does not take
office within 60 days after the retiring Trustee resigns or is removed, the retiring Trustee, the Company or the Holders of at least a majority in principal amount of the Securities of the applicable Series may petition any court of competent
jurisdiction for the appointment of a successor Trustee. 
 A successor Trustee shall deliver a written acceptance of its appointment to the
retiring Trustee and to the Company. Immediately after that, the retiring Trustee shall transfer all property held by it as Trustee to the successor Trustee subject to the lien provided for in Section 7.7, the resignation or removal of the
retiring Trustee shall become effective, and the successor Trustee shall have all the rights, powers and duties of the Trustee with respect to each Series of Securities for which it is acting as Trustee under this Indenture. A successor Trustee
shall mail a notice of its succession to each Securityholder of each such Series. Notwithstanding replacement of the Trustee pursuant to this Section 7.8, the Company’s obligations under Section 7.7 hereof shall continue for the
benefit of the retiring Trustee with respect to expenses and liabilities incurred by it for actions taken or omitted to be taken in accordance with its rights, powers and duties under this Indenture prior to such replacement. 

Section 7.9. Successor Trustee by Merger, Etc. 

If the Trustee consolidates with, merges or converts into, or transfers all or substantially all of its corporate trust business to, another
corporation, the successor corporation without any further act shall be the successor Trustee, subject to Section 
7.10. 
 Section 7.10. Eligibility; Disqualification. 

This Indenture shall always have a Trustee who satisfies the requirements of TIA § 310(a)(1), (2) and (5). The Trustee shall always have
a combined capital and surplus of at least $25,000,000 as set forth in its most recent published annual report of condition. The Trustee shall comply with TIA § 310(b). 

Section 7.11. Preferential Collection of Claims Against Company. 

The Trustee is subject to TIA § 311(a), excluding any creditor relationship listed in TIA § 311(b). A Trustee who has resigned or
been removed shall be subject to TIA § 311(a) to the extent indicated. 
 ARTICLE VIII. 

SATISFACTION AND DISCHARGE; DEFEASANCE 

Section 8.1. Satisfaction and Discharge of Indenture. 

This Indenture shall upon Company Order be discharged with respect to the Securities of any Series and cease to be of further effect as to all
Securities of such Series (except as hereinafter provided in this Section 8.1), and the Trustee, at the expense of the Company, shall execute instruments acknowledging satisfaction and discharge of this Indenture, when 

(a) either 

  
 31 

 (i) all Securities of such Series theretofore authenticated and delivered (other
than Securities that have been destroyed, lost or stolen and that have been replaced or paid) have been delivered to the Trustee for cancellation; or 

(ii) all such Securities of such Series not theretofore delivered to the Trustee for cancellation 

(1) have become due and payable by reason of sending a notice of redemption or otherwise, or 

(2) will become due and payable at their Stated Maturity within one year, or 

(3) have been called for redemption or are to be called for redemption within one year under arrangements satisfactory to
the Trustee for the giving of notice of redemption by the Trustee in the name, and at the expense, of the Company, or 

(4) are deemed paid and discharged pursuant to Section 8.3, as applicable; 

and the Company, in the case of (1), (2) or (3) above, shall have irrevocably deposited or caused to be deposited with the Trustee as trust funds in
trust an amount of money or U.S. Government Obligations, which amount shall be sufficient for the purpose of paying and discharging each installment of principal (including mandatory sinking fund or analogous payments) of and interest on all the
Securities of such Series on the dates such installments of principal or interest are due; 
 (b) the Company has paid
or caused to be paid all other sums payable hereunder by the Company; and 
 (c) the Company shall have delivered to the
Trustee an Officer’s Certificate and an Opinion of Counsel, each stating that all conditions precedent provided for relating to the satisfaction and discharge contemplated by this Section have been complied with. 

Notwithstanding the satisfaction and discharge of this Indenture, the obligations of the Company to the Trustee under Section 7.7, and,
if money shall have been deposited with the Trustee pursuant to clause (a) of this Section, the provisions of Sections 2.4, 2.7, 2.8, 8.2 and 8.5 shall survive. 

Section 8.2. Application of Trust Funds; Indemnification. 

(a) Subject to the provisions of Section 8.5, all money and U.S. Government Obligations or Foreign Government
Obligations deposited with the Trustee pursuant to Section 8.1, 8.3 or 8.4 and all money received by the Trustee in respect of U.S. Government Obligations or Foreign Government Obligations deposited with the Trustee pursuant to
Section 8.1, 8.3 or 8.4, shall be held in trust and applied by it, in accordance 

  
 32 

 
with the provisions of the Securities and this Indenture, to the payment, either directly or through any Paying Agent (including the Company acting as its own Paying Agent) as the Trustee may
determine, to the persons entitled thereto, of the principal and interest for whose payment such money has been deposited with or received by the Trustee or to make mandatory sinking fund payments or analogous payments as contemplated by Sections
8.1, 8.3 or 8.4. 
 (b) The Company shall pay and shall indemnify the Trustee against any tax, fee or other charge
imposed on or assessed against U.S. Government Obligations or Foreign Government Obligations deposited pursuant to Sections 8.1, 8.3 or 8.4 or the interest and principal received in respect of such obligations other than any payable by or on behalf
of Holders. 
 (c) The Trustee shall deliver or pay to the Company from time to time upon Company Order any U.S.
Government Obligations or Foreign Government Obligations or money held by it as provided in Sections 8.3 or 8.4 which, in the opinion of a nationally recognized firm of independent certified public accountants or investment bank expressed in a
written certification thereof delivered to the Trustee, are then in excess of the amount thereof which then would have been required to be deposited for the purpose for which such U.S. Government Obligations or Foreign Government Obligations or
money were deposited or received. This provision shall not authorize the sale by the Trustee of any U.S. Government Obligations or Foreign Government Obligations held under this Indenture. 

Section 8.3. Legal Defeasance of Securities of any Series. 

Unless this Section 8.3 is otherwise specified, pursuant to Section 2.2, to be inapplicable to Securities of any Series, the Company
shall be deemed to have paid and discharged the entire indebtedness on all the outstanding Securities of any Series on the 91st day after the date of the deposit referred to in subparagraph (d) hereof, and the provisions of this Indenture, as
it relates to such outstanding Securities of such Series, shall no longer be in effect (and the Trustee, at the expense of the Company, shall, upon receipt of a Company Order, execute instruments acknowledging the same), except as to: 

(a) the rights of Holders of Securities of such Series to receive, from the trust funds described in subparagraph
(d) hereof, (i) payment of the principal of and each installment of principal of and interest on the outstanding Securities of such Series on the Maturity of such principal or installment of principal or interest and (ii) the benefit of
any mandatory sinking fund payments applicable to the Securities of such Series on the day on which such payments are due and payable in accordance with the terms of this Indenture and the Securities of such Series; 

(b) the provisions of Sections 2.4, 2.5, 2.7, 2.8, 7.7, 8.2, 8.3, 8.5 and 8.6; and 

(c) the rights, powers, trusts and immunities of the Trustee hereunder and the Company’s obligations in connection
therewith; 
 provided that, the following conditions shall have been satisfied: 

  
 33 

 (1) the Company shall have irrevocably deposited or caused to be deposited
(except as provided in Section 8.2(c)) with the Trustee as trust funds specifically pledged as security for and dedicated solely to the benefit of the Holders of such Securities (i) in the case of Securities of such Series denominated in
Dollars, cash in Dollars and/or U.S. Government Obligations, or (ii) in the case of Securities of such Series denominated in a Foreign Currency (other than a composite currency), money and/or Foreign Government Obligations, which through the
payment of interest and principal in respect thereof in accordance with their terms, will provide (and without reinvestment and assuming no tax liability will be imposed on such Trustee), not later than one day before the due date of any payment of
money, an amount in cash, sufficient, in the opinion of a nationally recognized firm of independent public accountants or investment bank expressed in a written certification thereof delivered to the Trustee, to pay and discharge each installment of
principal of and interest, on and any mandatory sinking fund payments in respect of all the Securities of such Series on the dates such installments of principal or interest and such sinking fund payments are due; 

(2) such deposit will not result in a breach or violation of, or constitute a default under, this Indenture or any other
agreement or instrument to which the Company is a party or by which it is bound; 
 (3) no Default or Event of Default
with respect to the Securities of such Series shall have occurred and be continuing on the date of such deposit or during the period ending on the 91st day after such date; 

(4) the Company shall have delivered to the Trustee an Officer’s Certificate and an Opinion of Counsel to the effect
that (i) the Company has received from, or there has been published by, the Internal Revenue Service a ruling, or (ii) since the date of execution of this Indenture, there has been a change in the applicable Federal income tax law, in
either case to the effect that, and based thereon such Opinion of Counsel shall confirm that, the Holders of the Securities of such Series will not recognize income, gain or loss for Federal income tax purposes as a result of such deposit,
defeasance and discharge and will be subject to Federal income tax on the same amount and in the same manner and at the same times as would have been the case if such deposit, defeasance and discharge had not occurred; 

(5) the Company shall have delivered to the Trustee an Officer’s Certificate stating that the deposit was not made by
the Company with the intent of defeating, hindering, delaying or defrauding any other creditors of the Company; and 

(6) the Company shall have delivered to the Trustee an Officer’s Certificate and an Opinion of Counsel, each stating
that all conditions precedent provided for relating to the defeasance contemplated by this Section have been complied with. 
 
Section 8.4. Covenant Defeasance. 
 Unless this Section 8.4 is otherwise specified pursuant to Section 2.2
to be inapplicable to Securities of any Series, the Company may omit to comply with respect to the 

  
 34 

 
Securities of any Series with any term, provision or condition set forth under Sections 4.2, 4.3, 4.4 and 5.1 and, unless otherwise specified therein, any additional covenants specified in a
supplemental indenture for such Series of Securities or a Board Resolution or an Officer’s Certificate delivered pursuant to Section 2.2 (and the failure to comply with any such covenants shall not constitute a Default or Event of Default
with respect to such Series under Section 6.1) and the occurrence of any event specified in a supplemental indenture for such Series of Securities or a Board Resolution or an Officer’s Certificate delivered pursuant to Section 2.2 and
designated as an Event of Default shall not constitute a Default or Event of Default hereunder, with respect to the Securities of such Series, but, except as specified above, the remainder of this Indenture and such Securities will be unaffected
thereby; provided that the following conditions shall have been satisfied: 
 (a) with reference to this
Section 8.4, the Company has irrevocably deposited or caused to be irrevocably deposited (except as provided in Section 8.2(c)) with the Trustee as trust funds in trust for the purpose of making the following payments specifically pledged
as security for, and dedicated solely to, the benefit of the Holders of such Securities (i) in the case of Securities of such Series denominated in Dollars, cash in Dollars and/or U.S. Government Obligations, or (ii) in the case of
Securities of such Series denominated in a Foreign Currency (other than a composite currency), money and/or Foreign Government Obligations, which through the payment of interest and principal in respect thereof in accordance with their terms, will
provide (and without reinvestment and assuming no tax liability will be imposed on such Trustee), not later than one day before the due date of any payment of money, an amount in cash, sufficient, in the opinion of a nationally recognized firm of
independent certified public accountants or investment bank expressed in a written certification thereof delivered to the Trustee, to pay and discharge each installment of principal (including mandatory sinking fund or analogous payments) of and
interest on all the Securities of such Series on the dates such installments of principal or interest are due; 

(b) such deposit will not result in a breach or violation of, or constitute a default under, this Indenture or any other
agreement or instrument to which the Company is a party or by which it is bound; 
 (c) no Default or Event of Default
with respect to the Securities of such Series shall have occurred and be continuing on the date of such deposit; 

(d) the Company shall have delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel to the effect
that the Holders of the Securities of such Series will not recognize income, gain or loss for Federal income tax purposes as a result of such deposit, covenant defeasance and discharge and will be subject to Federal income tax on the same amount and
in the same manner and at the same times as would have been the case if such deposit, covenant defeasance and discharge had not occurred; 

  
 35 

 (e) The Company shall have delivered to the Trustee an Officer’s
Certificate stating the deposit was not made by the Company with the intent of defeating, hindering, delaying or defrauding any other creditors of the Company; and 

(f) The Company shall have delivered to the Trustee an Officer’s Certificate and an Opinion of Counsel, each stating
that all conditions precedent herein provided for relating to the covenant defeasance contemplated by this Section have been complied with. 

Section 8.5. Repayment to Company. 

Subject to applicable abandoned property law, the Trustee and the Paying Agent shall pay to the Company upon request any money held by them
for the payment of principal and interest that remains unclaimed for two years. After that, Securityholders entitled to the money must look to the Company for payment as general creditors unless an applicable abandoned property law designates
another person. 
 Section 8.6. Reinstatement. 

If the Trustee or the Paying Agent is unable to apply any money deposited with respect to Securities of any Series in accordance with
Section 8.1 by reason of any legal proceeding or by reason of any order or judgment of any court or governmental authority enjoining, restraining or otherwise prohibiting such application, the obligations of the Company under this Indenture
with respect to the Securities of such Series and under the Securities of such Series shall be revived and reinstated as though no deposit had occurred pursuant to Section 8.1 until such time as the Trustee or the Paying Agent is permitted to
apply all such money in accordance with Section 8.1; provided, however, that if the Company has made any payment of principal of or interest on or any Additional Amounts with respect to any Securities because of the reinstatement
of its obligations, the Company shall be subrogated to the rights of the Holders of such Securities to receive such payment from the money or U.S. Government Obligations held by the Trustee or Paying Agent after payment in full to the Holders. 

ARTICLE IX. 

AMENDMENTS AND WAIVERS 
 
Section 9.1. Without Consent of Holders. 
 The Company and the Trustee may amend or supplement this Indenture or the
Securities of one or more Series without the consent of any Securityholder: 
 (a) to cure any ambiguity, defect or
inconsistency; 
 (b) to comply with Article V; 

(c) to provide for uncertificated Securities in addition to or in place of certificated Securities; 

  
 36 

 (d) to add guarantees with respect to Securities of any Series or secure
Securities of any Series; 
 (e) to surrender any of the Company’s rights or powers under this Indenture; 

(f) to add covenants or events of default for the benefit of the holders of Securities of any Series; 

(g) to comply with the applicable procedures of the applicable depositary; 

(h) to make any change that does not adversely affect the rights of any Securityholder; 

(i) to provide for the issuance of and establish the form and terms and conditions of Securities of any Series as
permitted by this Indenture; 
 (j) to evidence and provide for the acceptance of appointment hereunder by a successor
Trustee or a separate Trustee with respect to the Securities of one or more Series and to add to or change any of the provisions of this Indenture as shall be necessary to provide for or facilitate the administration of the trusts hereunder by more
than one Trustee; or 
 (k) to comply with requirements of the SEC in order to effect or maintain the qualification of
this Indenture under the TIA. 
 Section 9.2. With Consent of Holders. 

The Company and the Trustee may enter into a supplemental indenture with the written consent of the Holders of at least a majority in
principal amount of the outstanding Securities of each Series affected by such supplemental indenture (including consents obtained in connection with a tender offer or exchange offer for the Securities of such Series), for the purpose of adding any
provisions to or changing in any manner or eliminating any of the provisions of this Indenture or of any supplemental indenture or of modifying in any manner the rights of the Securityholders of each such Series. Except as provided in
Section 6.13, the Holders of at least a majority in principal amount of the outstanding Securities of any Series by notice to the Trustee (including consents obtained in connection with a tender offer or exchange offer for the Securities of
such Series) may waive compliance by the Company with any provision of this Indenture or the Securities with respect to such Series. 
 It
shall not be necessary for the consent of the Holders of Securities under this Section 9.2 to approve the particular form of any proposed supplemental indenture or waiver, but it shall be sufficient if such consent approves the substance
thereof. After a supplemental indenture or waiver under this section becomes effective, the Company shall send to the Holders of Securities affected thereby, a notice briefly describing the supplemental indenture or waiver. Any failure by the
Company to send such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such supplemental indenture or waiver. 

  
 37 

 Section 9.3. Limitations. 

Without the consent of each Securityholder affected, an amendment or waiver may not: 

(a) reduce the principal amount of Securities whose Holders must consent to an amendment, supplement or waiver; 

(b) reduce the rate of or extend the time for payment of interest (including default interest) on any Security; 

(c) reduce the principal or change the Stated Maturity of any Security or reduce the amount of, or postpone the date fixed
for, the payment of any sinking fund or analogous obligation; 
 (d) reduce the principal amount of Discount Securities
payable upon acceleration of the maturity thereof; 
 (e) waive a Default or Event of Default in the payment of the
principal of or interest, if any, on any Security (except a rescission of acceleration of the Securities of any Series by the Holders of at least a majority in principal amount of the outstanding Securities of such Series and a waiver of the payment
default that resulted from such acceleration); 
 (f) make the principal of or interest, if any, on any Security payable
in any currency other than that stated in the Security; 
 (g) make any change in Sections 6.8, 6.13 or 9.3 (this
sentence); or 
 (h) waive a redemption payment with respect to any Security, provided that such redemption is made at
the Company’s option. 
 Section 9.4. Compliance with Trust Indenture Act. 

Every amendment to this Indenture or the Securities of one or more Series shall be set forth in a supplemental indenture hereto that complies
with the TIA as then in effect. 
 Section 9.5. Revocation and Effect of Consents. 

Until an amendment is set forth in a supplemental indenture or a waiver becomes effective, a consent to it by a Holder of a Security is a
continuing consent by the Holder and every subsequent Holder of a Security or portion of a Security that evidences the same debt as the consenting Holder’s Security, even if notation of the consent is not made on any Security. However, any such
Holder or subsequent Holder may revoke the consent as to his Security or portion of a Security if the Trustee receives the notice of revocation before the date of the supplemental indenture or the date the waiver becomes effective. 

  
 38 

 Any amendment or waiver once effective shall bind every Securityholder of each Series affected by
such amendment or waiver unless it is of the type described in any of clauses (a) through (h) of Section 9.3. In that case, the amendment or waiver shall bind each Holder of a Security who has consented to it and every subsequent Holder of
a Security or portion of a Security that evidences the same debt as the consenting Holder’s Security. 
 The Company may, but shall not
be obligated to, fix a record date for the purpose of determining the Holders entitled to give their consent or take any other action described above or required or permitted to be taken pursuant to this Indenture. If a record date is fixed, then
notwithstanding the second immediately preceding paragraph, those Persons who were Holders at such record date (or their duly designated proxies), and only those persons, shall be entitled to give such consent or to revoke any consent previously
given or take any such action, whether or not such Persons continue to be Holders after such record date. No such consent shall be valid or effective for more than 120 days after such record date. 

Section 9.6. Notation on or Exchange of Securities. 

The Company or the Trustee may place an appropriate notation about an amendment or waiver on any Security of any Series thereafter
authenticated. The Company in exchange for Securities of that Series may issue and the Trustee shall authenticate upon receipt of a Company Order in accordance with Section 2.3 new Securities of that Series that reflect the amendment or waiver.

 Section 9.7. Trustee Protected. 

In executing, or accepting the additional trusts created by, any supplemental indenture permitted by this Article or the modifications thereby
of the trusts created by this Indenture, the Trustee shall be entitled to receive, and (subject to Section 7.1) shall be fully protected in relying upon, an Officer’s Certificate or an Opinion of Counsel or both complying with
Section 10.4. The Trustee shall sign all supplemental indentures upon delivery of such an Officer’s Certificate or Opinion of Counsel or both, except that the Trustee need not sign any supplemental indenture that adversely affects its
rights, duties, liabilities or immunities under this Indenture. 
 ARTICLE X. 

MISCELLANEOUS 
 
Section 10.1. Trust Indenture Act Controls. 
 If any provision of this Indenture limits, qualifies, or conflicts with
another provision which is required or deemed to be included in this Indenture by the TIA, such required or deemed provision shall control. 

Section 10.2. Notices. 

Any notice or communication by the Company or the Trustee to the other, or by a Holder to the Company or the Trustee, is duly given if in
writing and delivered in person or mailed by first-class mail (registered or certified, return receipt requested), facsimile 

  
 39 

 
transmission, email or overnight air courier guaranteeing next day delivery, to the others’ address: 

if to the Company: 
 BROADCOM INC. 

1320 Ridder Park Drive 
 San Jose,
California 95131 
 Attention: Mark D. Brazeal 

Telephone: (408) 433-6336 

with a copy to: 
 Latham & Watkins LLP

 140 Scott Drive 
 Menlo Park,
California 95131 
 Attention: Anthony J. Richmond 

Telephone: (650) 463-2643 

if to the Trustee: 
 Wilmington Trust, National
Association 
 50 South Sixth Street, Suite 1290 

Minneapolis, Minnesota 55402 

Attention: Broadcom Inc. Administrator 

Facsimile: (612) 217-5651 

with a copy to: 
 Shipman & Goodwin LLP

 One Constitution Plaza 

Hartford, Connecticut 06103 

Attention: Marie C. Pollio 

Telephone: (860) 251-5561 

The Company or the Trustee by notice to the other may designate additional or different addresses for subsequent notices or communications.

 Any notice or communication to a Securityholder shall be sent electronically or by first-class mail to his, her or its address shown on
the register kept by the Registrar, in accordance with the procedures of the Depositary. Failure to send a notice or communication to a Securityholder of any Series or any defect in it shall not affect its sufficiency with respect to other
Securityholders of that or any other Series. 
 If a notice or communication is sent or published in the manner provided above, within the
time prescribed, it is duly given, whether or not the Securityholder receives it. 

  
 40 

 If the Company sends a notice or communication to Securityholders, it shall send a copy to the
Trustee and each Agent at the same time. 
 Notwithstanding any other provision of this Indenture or any Security, where this Indenture or
any Security provides for notice of any event (including any notice of redemption) to a Holder of a Global Security (whether by mail or otherwise), such notice shall be sufficiently given to the Depositary for such Security (or its designee)
pursuant to the customary procedures of such Depositary. 
 Section 10.3. Communication by
Holders with Other Holders. 
 Securityholders of any Series may communicate pursuant to TIA § 312(b) with other Securityholders of
that Series or any other Series with respect to their rights under this Indenture or the Securities of that Series or all Series. The Company, the Trustee, the Registrar and anyone else shall have the protection of TIA § 312(c). 

Section 10.4. Certificate and Opinion as to Conditions Precedent. 

Upon any request or application by the Company to the Trustee to take any action under this Indenture, the Company shall furnish to the
Trustee: 
 (a) an Officer’s Certificate stating that, in the opinion of the signers, all conditions precedent, if
any, provided for in this Indenture relating to the proposed action have been complied with; and 
 (b) an Opinion of
Counsel stating that, in the opinion of such counsel, all such conditions precedent have been complied with. 

Section 10.5. Statements Required in Certificate or Opinion. 

Each certificate or opinion with respect to compliance with a condition or covenant provided for in this Indenture (other than a certificate
provided pursuant to TIA § 314(a)(4)) shall comply with the provisions of TIA § 314(e) and shall include: 

(a) a statement that the person making such certificate or opinion has read such covenant or condition; 

(b) a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions
contained in such certificate or opinion are based; 
 (c) a statement that, in the opinion of such person, he has made
such examination or investigation as is necessary to enable him to express an informed opinion as to whether or not such covenant or condition has been complied with; and 

(d) a statement as to whether or not, in the opinion of such person, such condition or covenant has been complied with.

  
 41 

 Section 10.6. Rules by Trustee and Agents. 

The Trustee may make reasonable rules for action by or a meeting of Securityholders of one or more Series. Any Agent may make reasonable rules
and set reasonable requirements for its functions. 
 Section 10.7. Legal Holidays. 

A “Legal Holiday” is any day that is not a Business Day. If a payment date is a Legal Holiday at a place of payment, payment
may be made at that place on the next succeeding day that is not a Legal Holiday, and no interest shall accrue for the intervening period. 

Section 10.8. No Recourse Against Others. 

A director, officer, employee or stockholder (past or present), as such, of the Company shall not have any liability for any obligations of
the Company under the Securities or the Indenture or for any claim based on, in respect of or by reason of such obligations or their creation. Each Securityholder by accepting a Security waives and releases all such liability. The waiver and release
are part of the consideration for the issue of the Securities. 

Section 10.9. Counterparts. 

This Indenture may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so
executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. The exchange of copies of this Indenture and of signature pages by facsimile or PDF transmission shall constitute effective
execution and delivery of this Indenture as to the parties hereto and may be used in lieu of the original Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures
for all purposes. 
 Section 10.10. Governing Law; Waiver of Jury Trial; Consent to
Jurisdiction. 
 THIS INDENTURE AND THE SECURITIES, INCLUDING ANY CLAIM OR CONTROVERSY ARISING OUT OF OR RELATING TO THE INDENTURE OR
THE SECURITIES, SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK. 
 THE COMPANY, THE TRUSTEE AND THE HOLDERS (BY THEIR
ACCEPTANCE OF THE SECURITIES) EACH HEREBY IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE NOTES OR THE TRANSACTIONS
CONTEMPLATED HEREBY OR THEREBY. 
 Any legal suit, action or proceeding arising out of or based upon this Indenture or the transactions
contemplated hereby may be instituted in the federal courts of the United States of America located in the City of New York or the courts of the State of New York in each case located in the City of New York (collectively, the “Specified
Courts”), and each party 

  
 42 

 
irrevocably submits to the non exclusive jurisdiction of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail (to the extent allowed
under any applicable statute or rule of court) to such party’s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The Company, the Trustee and the Holders (by their
acceptance of the Securities) each hereby irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or
claim any such suit, action or other proceeding has been brought in an inconvenient forum. 

Section 10.11. No Adverse Interpretation of Other Agreements. 

This Indenture may not be used to interpret another indenture, loan or debt agreement of the Company or a Subsidiary of the Company. Any such
indenture, loan or debt agreement may not be used to interpret this Indenture. 

Section 10.12. Successors. 

All agreements of the Company in this Indenture and the Securities shall bind its successor. All agreements of the Trustee in this Indenture
shall bind its successor. 
 Section 10.13. Severability. 

In case any provision in this Indenture or in the Securities shall be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

Section 10.14. Table of Contents, Headings, Etc. 

The Table of Contents, Cross Reference Table, and headings of the Articles and Sections of this Indenture have been inserted for convenience
of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof. 
 
Section 10.15. Securities in a Foreign Currency. 
 Unless otherwise specified in a Board Resolution, a supplemental
indenture hereto or an Officer’s Certificate delivered pursuant to Section 2.2 of this Indenture with respect to a particular Series of Securities, whenever for purposes of this Indenture any action may be taken by the Holders of a
specified percentage in aggregate principal amount of Securities of all Series or all Series affected by a particular action at the time outstanding and, at such time, there are outstanding Securities of any Series which are denominated in more than
one currency, then the principal amount of Securities of such Series which shall be deemed to be outstanding for the purpose of taking such action shall be determined by converting any such other currency into a currency that is designated upon
issuance of any particular Series of Securities. Unless otherwise specified in a Board Resolution, a supplemental indenture hereto or an Officer’s Certificate delivered pursuant to Section 2.2 of this Indenture with respect to a particular
Series of Securities, such conversion shall be at the spot rate for the purchase of the designated currency 

  
 43 

 
as published in The Financial Times in the “Currency Rates” section (or, if The Financial Times is no longer published, or if such information is no longer available in The Financial
Times, such source as may be selected in good faith by the Company) on any date of determination. The provisions of this paragraph shall apply in determining the equivalent principal amount in respect of Securities of a Series denominated in
currency other than Dollars in connection with any action taken by Holders of Securities pursuant to the terms of this Indenture. 
 All
decisions and determinations provided for in the preceding paragraph shall, in the absence of manifest error, to the extent permitted by law, be conclusive for all purposes and irrevocably binding upon the Trustee and all Holders. 

Section 10.16. Judgment Currency. 

The Company agrees, to the fullest extent that it may effectively do so under applicable law, that (a) if for the purpose of obtaining
judgment in any court it is necessary to convert the sum due in respect of the principal of or interest or other amount on the Securities of any Series (the “Required Currency”) into a currency in which a judgment will be rendered
(the “Judgment Currency”), the rate of exchange used shall be the rate at which in accordance with normal banking procedures the Trustee could purchase in The City of New York the Required Currency with the Judgment Currency on the
day on which final unappealable judgment is entered, unless such day is not a New York Banking Day, then the rate of exchange used shall be the rate at which in accordance with normal banking procedures the Trustee could purchase in The City of New
York the Required Currency with the Judgment Currency on the New York Banking Day preceding the day on which final unappealable judgment is entered and (b) its obligations under this Indenture to make payments in the Required Currency
(i) shall not be discharged or satisfied by any tender, any recovery pursuant to any judgment (whether or not entered in accordance with subsection (a)), in any currency other than the Required Currency, except to the extent that such tender or
recovery shall result in the actual receipt, by the payee, of the full amount of the Required Currency expressed to be payable in respect of such payments, (ii) shall be enforceable as an alternative or additional cause of action for the
purpose of recovering in the Required Currency the amount, if any, by which such actual receipt shall fall short of the full amount of the Required Currency so expressed to be payable, and (iii) shall not be affected by judgment being obtained
for any other sum due under this Indenture. For purposes of the foregoing, “New York Banking Day” means any day except a Saturday, Sunday or a legal holiday in The City of New York on which banking institutions are authorized or
required by law, regulation or executive order to close. 
 Section 10.17. Force Majeure.

 In no event shall the Trustee be responsible or liable for any failure or delay in the performance of its obligations hereunder arising
out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural catastrophes or acts of God, and
interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services, it being understood that the Trustee shall use reasonable best efforts which are consistent with accepted practices in the banking
industry to resume performance as soon as practicable under the circumstances. 

  
 44 

 Section 10.18. U.S.A. Patriot Act. 

The parties hereto acknowledge that in accordance with Section 326 of the U.S.A. Patriot Act, the Trustee is required to obtain, verify,
and record information that identifies each person or legal entity that establishes a relationship or opens an account with the Trustee. The parties to this Indenture agree that they will provide the Trustee with such information as it may request
in order for the Trustee to satisfy the requirements of the U.S.A. Patriot Act. 
 ARTICLE XI. 

SINKING FUNDS 
 
Section 11.1. Applicability of Article. 
 The provisions of this Article shall be applicable to any sinking fund for
the retirement of the Securities of a Series if so provided by the terms of such Securities pursuant to Section 2.2 and except as otherwise permitted or required by any form of Security of such Series issued pursuant to this Indenture. 

The minimum amount of any sinking fund payment provided for by the terms of the Securities of any Series is herein referred to as a
“mandatory sinking fund payment” and any other amount provided for by the terms of Securities of such Series is herein referred to as an “optional sinking fund payment.” If provided for by the terms of Securities of
any Series, the cash amount of any sinking fund payment may be subject to reduction as provided in Section 11.2. Each sinking fund payment shall be applied to the redemption of Securities of any Series as provided for by the terms of the
Securities of such Series. 
 Section 11.2. Satisfaction of Sinking Fund Payments with
Securities. 
 The Company may, in satisfaction of all or any part of any sinking fund payment with respect to the Securities of any
Series to be made pursuant to the terms of such Securities (1) deliver outstanding Securities of such Series to which such sinking fund payment is applicable (other than any of such Securities previously called for mandatory sinking fund
redemption) and (2) apply as credit Securities of such Series to which such sinking fund payment is applicable and which have been repurchased by the Company or redeemed either at the election of the Company pursuant to the terms of such Series
of Securities (except pursuant to any mandatory sinking fund) or through the application of permitted optional sinking fund payments or other optional redemptions pursuant to the terms of such Securities, provided that such Securities have not been
previously so credited. Such Securities shall be received by the Trustee, together with an Officer’s Certificate with respect thereto, not later than 15 days prior to the date on which the Trustee begins the process of selecting Securities for
redemption, and shall be credited for such purpose by the Trustee at the price specified in such Securities for redemption through operation of the sinking fund and the amount of such sinking fund payment shall be reduced accordingly. If as a result
of the delivery or credit of Securities in lieu of cash payments pursuant to this Section 11.2, the principal amount of Securities of such Series to be redeemed in order to exhaust the aforesaid cash payment shall be less than $100,000, the
Trustee need not call Securities of such Series for redemption, except upon receipt of a Company Order that such action be taken, and such cash payment shall be held by the Trustee or a Paying Agent 

  
 45 

 
and applied to the next succeeding sinking fund payment, provided, however, that the Trustee or such Paying Agent shall from time to time upon receipt of a Company Order pay over
and deliver to the Company any cash payment so being held by the Trustee or such Paying Agent upon delivery by the Company to the Trustee of Securities of that Series purchased by the Company having an unpaid principal amount equal to the cash
payment required to be released to the Company. 
 Section 11.3. Redemption of Securities for
Sinking Fund. 
 Not less than 45 days (unless otherwise indicated in the Board Resolution, supplemental indenture hereto or
Officer’s Certificate in respect of a particular Series of Securities) prior to each sinking fund payment date for any Series of Securities, the Company will deliver to the Trustee an Officer’s Certificate specifying the amount of the next
ensuing mandatory sinking fund payment for that Series pursuant to the terms of that Series, the portion thereof, if any, which is to be satisfied by payment of cash and the portion thereof, if any, which is to be satisfied by delivering and
crediting of Securities of that Series pursuant to Section 11.2, and the optional amount, if any, to be added in cash to the next ensuing mandatory sinking fund payment, and the Company shall thereupon be obligated to pay the amount therein
specified. Not less than 30 days (unless otherwise indicated in the Board Resolution, Officer’s Certificate or supplemental indenture in respect of a particular Series of Securities) before each such sinking fund payment date the Securities to
be redeemed upon such sinking fund payment date will be selected in the manner specified in Section 3.2 and the Company shall send or cause to be sent a notice of the redemption thereof to be given in the name of and at the expense of the
Company in the manner provided in and in accordance with Section 3.3. Such notice having been duly given, the redemption of such Securities shall be made upon the terms and in the manner stated in Sections 3.4, 3.5 and 3.6. 

  
 46 

 IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed as of the
day and year first above written. 
  

			
	BROADCOM INC.
		
	By:	 	  

		 	Name:
		 	Its:
	
	WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee
		
	By:	 	  

		 	Name:
		 	Its:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}]]